Ignite Creation Date:
2025-12-25 @ 3:53 AM
Ignite Modification Date:
2025-12-26 @ 2:42 AM
Study NCT ID:
NCT04425902
Status:
COMPLETED
Last Update Posted:
2024-01-05
First Post:
2020-06-05
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015658', 'term': 'HIV Infections'}, {'id': 'D000163', 'term': 'Acquired Immunodeficiency Syndrome'}, {'id': 'D007239', 'term': 'Infections'}], 'ancestors': [{'id': 'D000086982', 'term': 'Blood-Borne Infections'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D015229', 'term': 'Sexually Transmitted Diseases, Viral'}, {'id': 'D012749', 'term': 'Sexually Transmitted Diseases'}, {'id': 'D016180', 'term': 'Lentivirus Infections'}, {'id': 'D012192', 'term': 'Retroviridae Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D007153', 'term': 'Immunologic Deficiency Syndromes'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D012897', 'term': 'Slow Virus Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000723722', 'term': 'GSK3640254'}, {'id': 'D002110', 'term': 'Caffeine'}, {'id': 'D008790', 'term': 'Metoprolol'}, {'id': 'C093875', 'term': 'montelukast'}, {'id': 'D005480', 'term': 'Flurbiprofen'}, {'id': 'D009853', 'term': 'Omeprazole'}, {'id': 'D008874', 'term': 'Midazolam'}, {'id': 'D004077', 'term': 'Digoxin'}, {'id': 'D017035', 'term': 'Pravastatin'}], 'ancestors': [{'id': 'D014970', 'term': 'Xanthines'}, {'id': 'D000470', 'term': 'Alkaloids'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D011688', 'term': 'Purinones'}, {'id': 'D011687', 'term': 'Purines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D050198', 'term': 'Phenoxypropanolamines'}, {'id': 'D011412', 'term': 'Propanolamines'}, {'id': 'D000605', 'term': 'Amino Alcohols'}, {'id': 'D000438', 'term': 'Alcohols'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D020005', 'term': 'Propanols'}, {'id': 'D000588', 'term': 'Amines'}, {'id': 'D011422', 'term': 'Propionates'}, {'id': 'D000144', 'term': 'Acids, Acyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}, {'id': 'D001713', 'term': 'Biphenyl Compounds'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D053799', 'term': '2-Pyridinylmethylsulfinylbenzimidazoles'}, {'id': 'D013454', 'term': 'Sulfoxides'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D011725', 'term': 'Pyridines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D001562', 'term': 'Benzimidazoles'}, {'id': 'D001569', 'term': 'Benzodiazepines'}, {'id': 'D001552', 'term': 'Benzazepines'}, {'id': 'D004071', 'term': 'Digitalis Glycosides'}, {'id': 'D002298', 'term': 'Cardenolides'}, {'id': 'D002301', 'term': 'Cardiac Glycosides'}, {'id': 'D002297', 'term': 'Cardanolides'}, {'id': 'D013256', 'term': 'Steroids'}, {'id': 'D000072473', 'term': 'Fused-Ring Compounds'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D006027', 'term': 'Glycosides'}, {'id': 'D002241', 'term': 'Carbohydrates'}, {'id': 'D009281', 'term': 'Naphthalenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'GSKClinicalSupportHD@gsk.com', 'phone': '866-435-7343', 'title': 'GSK Response Center', 'organization': 'ViiV Healthcare'}, 'certainAgreement': {'otherDetails': 'GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 26', 'description': 'Safety Population consisted of all participants who received at least 1 dose of study medication.', 'eventGroups': [{'id': 'EG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.', 'otherNumAtRisk': 20, 'deathsNumAtRisk': 20, 'otherNumAffected': 1, 'seriousNumAtRisk': 20, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.', 'otherNumAtRisk': 20, 'deathsNumAtRisk': 20, 'otherNumAffected': 5, 'seriousNumAtRisk': 20, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.', 'otherNumAtRisk': 19, 'deathsNumAtRisk': 19, 'otherNumAffected': 5, 'seriousNumAtRisk': 19, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 19, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 19, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'Taste disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 19, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 19, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'Abdominal discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 19, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 19, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'Dermatitis contact', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 19, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 19, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'Rash maculo-papular', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 19, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'Rash papular', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 19, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'Dry throat', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 19, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'Epistaxis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 19, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time t (AUC[0-t]) for Caffeine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '37970', 'spread': '31.1', 'groupId': 'OG000'}, {'value': '42230', 'spread': '32.4', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.11', 'ciLowerLimit': '0.94', 'ciUpperLimit': '1.32', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine. Area under the plasma concentration-time curve from time zero to time t, to be calculated using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'Hour*nanograms per milliliter (h*ng/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The Pharmacokinetic (PK) Parameter Population included all participants who underwent plasma PK sampling and had evaluable PK parameters estimated. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'AUC From Time Zero Extrapolated to Infinity (AUC[0-infinity]) for Caffeine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '39720', 'spread': '30.6', 'groupId': 'OG000'}, {'value': '44440', 'spread': '30.6', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.12', 'ciLowerLimit': '0.95', 'ciUpperLimit': '1.32', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Maximum Observed Plasma Concentration (Cmax) for Caffeine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '4340', 'spread': '22.1', 'groupId': 'OG000'}, {'value': '4110', 'spread': '25.9', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.95', 'ciLowerLimit': '0.83', 'ciUpperLimit': '1.08', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine.', 'unitOfMeasure': 'Nanograms per milliliter (ng/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Time to Cmax (Tmax) for Caffeine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.000', 'groupId': 'OG000', 'lowerLimit': '1.00', 'upperLimit': '6.00'}, {'value': '3.000', 'groupId': 'OG001', 'lowerLimit': '0.50', 'upperLimit': '6.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Apparent Terminal Phase Half-life (t1/2) for Caffeine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '5.380', 'spread': '21.2', 'groupId': 'OG000'}, {'value': '6.085', 'spread': '17.4', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'AUC(0-t) for Metoprolol', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '655.0', 'spread': '135.2', 'groupId': 'OG000'}, {'value': '807.3', 'spread': '136.4', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.23', 'ciLowerLimit': '0.71', 'ciUpperLimit': '2.14', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'AUC(0-infinity) for Metoprolol', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '659.1', 'spread': '134.4', 'groupId': 'OG000'}, {'value': '813.1', 'spread': '135.3', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.23', 'ciLowerLimit': '0.71', 'ciUpperLimit': '2.14', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Cmax for Metoprolol', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '127.4', 'spread': '90.0', 'groupId': 'OG000'}, {'value': '141.1', 'spread': '94.4', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.11', 'ciLowerLimit': '0.72', 'ciUpperLimit': '1.69', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Tmax for Metoprolol', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.000', 'groupId': 'OG000', 'lowerLimit': '1.00', 'upperLimit': '6.00'}, {'value': '3.000', 'groupId': 'OG001', 'lowerLimit': '1.00', 'upperLimit': '4.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 't1/2 for Metoprolol', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '4.872', 'spread': '65.6', 'groupId': 'OG000'}, {'value': '5.342', 'spread': '59.6', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'AUC(0-t) for Montelukast', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '2724', 'spread': '19.9', 'groupId': 'OG000'}, {'value': '2940', 'spread': '18.4', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.08', 'ciLowerLimit': '0.97', 'ciUpperLimit': '1.20', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'AUC(0-infinity) for Montelukast', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '2859', 'spread': '20.6', 'groupId': 'OG000'}, {'value': '3109', 'spread': '18.6', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.09', 'ciLowerLimit': '0.98', 'ciUpperLimit': '1.21', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Cmax for Montelukast', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '379.8', 'spread': '25.2', 'groupId': 'OG000'}, {'value': '393.5', 'spread': '19.5', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.04', 'ciLowerLimit': '0.92', 'ciUpperLimit': '1.17', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast.', 'unitOfMeasure': 'Nanograms per milliliter (ng/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Tmax for Montelukast', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '5.000', 'groupId': 'OG000', 'lowerLimit': '2.00', 'upperLimit': '8.03'}, {'value': '6.000', 'groupId': 'OG001', 'lowerLimit': '3.00', 'upperLimit': '8.07'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 't1/2 for Montelukast', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '5.035', 'spread': '10.2', 'groupId': 'OG000'}, {'value': '5.135', 'spread': '7.4', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'AUC(0-t) for Flurbiprofen', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '64930', 'spread': '28.9', 'groupId': 'OG000'}, {'value': '66170', 'spread': '27.6', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.02', 'ciLowerLimit': '0.88', 'ciUpperLimit': '1.18', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'AUC(0-infinity) for Flurbiprofen', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '66700', 'spread': '28.1', 'groupId': 'OG000'}, {'value': '68660', 'spread': '26.7', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.03', 'ciLowerLimit': '0.89', 'ciUpperLimit': '1.19', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Cmax for Flurbiprofen', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '10220', 'spread': '24.7', 'groupId': 'OG000'}, {'value': '10710', 'spread': '19.8', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.05', 'ciLowerLimit': '0.93', 'ciUpperLimit': '1.18', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Tmax for Flurbiprofen', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.000', 'groupId': 'OG000', 'lowerLimit': '1.00', 'upperLimit': '8.03'}, {'value': '4.000', 'groupId': 'OG001', 'lowerLimit': '1.00', 'upperLimit': '6.07'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 't1/2 for Flurbiprofen', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.123', 'spread': '31.0', 'groupId': 'OG000'}, {'value': '6.088', 'spread': '30.4', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'AUC(0-t) for Omeprazole', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '728.1', 'spread': '114.7', 'groupId': 'OG000'}, {'value': '817.9', 'spread': '82.1', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.12', 'ciLowerLimit': '0.72', 'ciUpperLimit': '1.75', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'AUC(0-infinity) for Omeprazole', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '11', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '1127', 'spread': '98.6', 'groupId': 'OG000'}, {'value': '1093', 'spread': '75.5', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.97', 'ciLowerLimit': '0.54', 'ciUpperLimit': '1.73', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Cmax for Omeprazole', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '224.4', 'spread': '121.6', 'groupId': 'OG000'}, {'value': '256.6', 'spread': '72.0', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.14', 'ciLowerLimit': '0.73', 'ciUpperLimit': '1.78', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Tmax for Omeprazole', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.000', 'groupId': 'OG000', 'lowerLimit': '1.50', 'upperLimit': '12.07'}, {'value': '6.000', 'groupId': 'OG001', 'lowerLimit': '1.50', 'upperLimit': '12.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 't1/2 for Omeprazole', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '11', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.439', 'spread': '32.0', 'groupId': 'OG000'}, {'value': '1.219', 'spread': '28.1', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'AUC(0-t) for Midazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '67.11', 'spread': '31.3', 'groupId': 'OG000'}, {'value': '62.95', 'spread': '31.0', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.94', 'ciLowerLimit': '0.80', 'ciUpperLimit': '1.11', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'AUC(0-infinity) for Midazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '70.08', 'spread': '31.4', 'groupId': 'OG000'}, {'value': '65.46', 'spread': '31.2', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.93', 'ciLowerLimit': '0.79', 'ciUpperLimit': '1.10', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Cmax for Midazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '15.44', 'spread': '39.5', 'groupId': 'OG000'}, {'value': '13.95', 'spread': '42.3', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.90', 'ciLowerLimit': '0.73', 'ciUpperLimit': '1.12', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Tmax for Midazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.000', 'groupId': 'OG000', 'lowerLimit': '0.25', 'upperLimit': '2.00'}, {'value': '1.000', 'groupId': 'OG001', 'lowerLimit': '0.25', 'upperLimit': '4.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 't1/2 for Midazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '5.756', 'spread': '13.2', 'groupId': 'OG000'}, {'value': '5.222', 'spread': '20.6', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'AUC(0-t) for Digoxin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '16690', 'spread': '21.7', 'groupId': 'OG000'}, {'value': '17840', 'spread': '26.9', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.07', 'ciLowerLimit': '0.94', 'ciUpperLimit': '1.22', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'Hours*picogram per milliliter (h*pg/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'AUC(0-infinity) for Digoxin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '19180', 'spread': '21.5', 'groupId': 'OG000'}, {'value': '20090', 'spread': '27.1', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.05', 'ciLowerLimit': '0.92', 'ciUpperLimit': '1.19', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*pg/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Cmax for Digoxin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '1026', 'spread': '48.3', 'groupId': 'OG000'}, {'value': '1282', 'spread': '56.5', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.25', 'ciLowerLimit': '0.96', 'ciUpperLimit': '1.63', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin.', 'unitOfMeasure': 'Picogram per milliliter (pg/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Tmax for Digoxin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.000', 'groupId': 'OG000', 'lowerLimit': '1.50', 'upperLimit': '6.00'}, {'value': '2.000', 'groupId': 'OG001', 'lowerLimit': '1.00', 'upperLimit': '4.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 't1/2 for Digoxin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '40.279', 'spread': '14.3', 'groupId': 'OG000'}, {'value': '38.784', 'spread': '12.0', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'AUC(0-t) for Pravastatin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '69.92', 'spread': '63.9', 'groupId': 'OG000'}, {'value': '51.03', 'spread': '75.5', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.73', 'ciLowerLimit': '0.52', 'ciUpperLimit': '1.03', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'AUC(0-infinity) for Pravastatin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '16', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '72.09', 'spread': '62.9', 'groupId': 'OG000'}, {'value': '43.70', 'spread': '47.5', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.61', 'ciLowerLimit': '0.45', 'ciUpperLimit': '0.82', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Cmax for Pravastatin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '19.45', 'spread': '79.8', 'groupId': 'OG000'}, {'value': '15.19', 'spread': '76.9', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.78', 'ciLowerLimit': '0.54', 'ciUpperLimit': '1.14', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 'Tmax for Pravastatin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.500', 'groupId': 'OG000', 'lowerLimit': '0.50', 'upperLimit': '6.00'}, {'value': '3.000', 'groupId': 'OG001', 'lowerLimit': '1.00', 'upperLimit': '4.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'PRIMARY', 'title': 't1/2 for Pravastatin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '16', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.189', 'spread': '43.4', 'groupId': 'OG000'}, {'value': '3.156', 'spread': '47.2', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}, {'id': 'OG002', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'AEs', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}]}]}, {'title': 'SAEs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 26', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAE was defined as any untoward medical occurrence that, at any dose, results in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect and other situations according to medical or scientific judgement.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Baseline (Day -1): Platelet count', 'categories': [{'measurements': [{'value': '258.6', 'spread': '59.14', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Platelet count', 'categories': [{'measurements': [{'value': '265.9', 'spread': '60.21', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Leukocyte count', 'categories': [{'measurements': [{'value': '5.64', 'spread': '1.338', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Leukocyte count', 'categories': [{'measurements': [{'value': '6.30', 'spread': '1.343', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Neutrophils', 'categories': [{'measurements': [{'value': '3.1504', 'spread': '1.25074', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Neutrophils', 'categories': [{'measurements': [{'value': '3.7430', 'spread': '1.27763', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Lymphocytes', 'categories': [{'measurements': [{'value': '1.8217', 'spread': '0.39628', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Lymphocytes', 'categories': [{'measurements': [{'value': '1.8965', 'spread': '0.33426', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Monocytes', 'categories': [{'measurements': [{'value': '0.4890', 'spread': '0.15889', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Monocytes', 'categories': [{'measurements': [{'value': '0.4515', 'spread': '0.12708', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Eosinophils', 'categories': [{'measurements': [{'value': '0.1461', 'spread': '0.15067', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Eosinophils', 'categories': [{'measurements': [{'value': '0.1610', 'spread': '0.15071', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Basophils', 'categories': [{'measurements': [{'value': '0.0331', 'spread': '0.01657', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Basophils', 'categories': [{'measurements': [{'value': '0.0440', 'spread': '0.01569', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.', 'unitOfMeasure': '10^9 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Baseline (Day 10): Platelet count', 'categories': [{'measurements': [{'value': '265.9', 'spread': '60.21', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Platelet count', 'categories': [{'measurements': [{'value': '261.9', 'spread': '58.51', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Leukocyte count', 'categories': [{'measurements': [{'value': '6.30', 'spread': '1.343', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Leukocyte count', 'categories': [{'measurements': [{'value': '5.79', 'spread': '1.192', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Neutrophils', 'categories': [{'measurements': [{'value': '3.7430', 'spread': '1.27763', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Neutrophils', 'categories': [{'measurements': [{'value': '3.2680', 'spread': '1.17833', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Lymphocytes', 'categories': [{'measurements': [{'value': '1.8965', 'spread': '0.33426', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Lymphocytes', 'categories': [{'measurements': [{'value': '1.8355', 'spread': '0.52512', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Monocytes', 'categories': [{'measurements': [{'value': '0.4515', 'spread': '0.12708', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Monocytes', 'categories': [{'measurements': [{'value': '0.4435', 'spread': '0.16662', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Eosinophils', 'categories': [{'measurements': [{'value': '0.1610', 'spread': '0.15071', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Eosinophils', 'categories': [{'measurements': [{'value': '0.1920', 'spread': '0.18981', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Basophils', 'categories': [{'measurements': [{'value': '0.0440', 'spread': '0.01569', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Basophils', 'categories': [{'measurements': [{'value': '0.0460', 'spread': '0.02981', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.', 'unitOfMeasure': '10^9 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Baseline (Day 20): Platelet count', 'categories': [{'measurements': [{'value': '262.3', 'spread': '60.09', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Platelet count', 'categories': [{'measurements': [{'value': '249.2', 'spread': '51.84', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Platelet count', 'categories': [{'measurements': [{'value': '260.7', 'spread': '54.96', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Leukocyte count', 'categories': [{'measurements': [{'value': '5.86', 'spread': '1.184', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Leukocyte count', 'categories': [{'measurements': [{'value': '5.81', 'spread': '1.400', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Leukocyte count', 'categories': [{'measurements': [{'value': '5.98', 'spread': '1.255', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Neutrophils', 'categories': [{'measurements': [{'value': '3.3179', 'spread': '1.18871', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Neutrophils', 'categories': [{'measurements': [{'value': '3.1925', 'spread': '1.29353', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Neutrophils', 'categories': [{'measurements': [{'value': '3.4529', 'spread': '1.16823', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Lymphocytes', 'categories': [{'measurements': [{'value': '1.8437', 'spread': '0.53820', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Lymphocytes', 'categories': [{'measurements': [{'value': '1.8787', 'spread': '0.57389', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Lymphocytes', 'categories': [{'measurements': [{'value': '1.9280', 'spread': '0.63546', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Monocytes', 'categories': [{'measurements': [{'value': '0.4505', 'spread': '0.16811', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Monocytes', 'categories': [{'measurements': [{'value': '0.4689', 'spread': '0.14658', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Monocytes', 'categories': [{'measurements': [{'value': '0.3576', 'spread': '0.12355', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Eosinophils', 'categories': [{'measurements': [{'value': '0.1953', 'spread': '0.19443', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Eosinophils', 'categories': [{'measurements': [{'value': '0.2282', 'spread': '0.23748', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Eosinophils', 'categories': [{'measurements': [{'value': '0.1837', 'spread': '0.20635', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Basophils', 'categories': [{'measurements': [{'value': '0.0474', 'spread': '0.02997', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Basophils', 'categories': [{'measurements': [{'value': '0.0380', 'spread': '0.02395', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Basophils', 'categories': [{'measurements': [{'value': '0.0408', 'spread': '0.02134', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.', 'unitOfMeasure': '10^9 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Absolute Values of Hematocrit', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Baseline (Day -1)', 'categories': [{'measurements': [{'value': '0.4188', 'spread': '0.03442', 'groupId': 'OG000'}]}]}, {'title': 'Day 10', 'categories': [{'measurements': [{'value': '0.4098', 'spread': '0.03577', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.', 'unitOfMeasure': 'Proportion of red blood cells in blood', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Absolute Values of Hematocrit', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Baseline (Day 10)', 'categories': [{'measurements': [{'value': '0.4098', 'spread': '0.03577', 'groupId': 'OG000'}]}]}, {'title': 'Day 20', 'categories': [{'measurements': [{'value': '0.4216', 'spread': '0.03420', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.', 'unitOfMeasure': 'Proportion of red blood cells in blood', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Absolute Values of Hematocrit', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Baseline (Day 20)', 'categories': [{'measurements': [{'value': '0.4239', 'spread': '0.03352', 'groupId': 'OG000'}]}]}, {'title': 'Day 22', 'categories': [{'measurements': [{'value': '0.4022', 'spread': '0.04433', 'groupId': 'OG000'}]}]}, {'title': 'Day 25', 'categories': [{'measurements': [{'value': '0.4168', 'spread': '0.04079', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.', 'unitOfMeasure': 'Proportion of red blood cells in blood', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Absolute Values of Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Baseline (Day -1)', 'categories': [{'measurements': [{'value': '141.9', 'spread': '13.27', 'groupId': 'OG000'}]}]}, {'title': 'Day 10', 'categories': [{'measurements': [{'value': '137.7', 'spread': '13.07', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Absolute Values of Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Baseline (Day 10)', 'categories': [{'measurements': [{'value': '137.7', 'spread': '13.07', 'groupId': 'OG000'}]}]}, {'title': 'Day 20', 'categories': [{'measurements': [{'value': '140.0', 'spread': '12.22', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Absolute Values of Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Baseline (Day 20)', 'categories': [{'measurements': [{'value': '140.6', 'spread': '12.21', 'groupId': 'OG000'}]}]}, {'title': 'Day 22', 'categories': [{'measurements': [{'value': '134.7', 'spread': '15.54', 'groupId': 'OG000'}]}]}, {'title': 'Day 25', 'categories': [{'measurements': [{'value': '138.3', 'spread': '13.83', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Absolute Values of Erythrocytes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Baseline (Day -1)', 'categories': [{'measurements': [{'value': '4.836', 'spread': '0.4125', 'groupId': 'OG000'}]}]}, {'title': 'Day 10', 'categories': [{'measurements': [{'value': '4.664', 'spread': '0.4459', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.', 'unitOfMeasure': '10^12 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Absolute Values of Erythrocytes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Baseline (Day 10)', 'categories': [{'measurements': [{'value': '4.664', 'spread': '0.4459', 'groupId': 'OG000'}]}]}, {'title': 'Day 20', 'categories': [{'measurements': [{'value': '4.746', 'spread': '0.3994', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.', 'unitOfMeasure': '10^12 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Absolute Values of Erythrocytes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Baseline (Day 20)', 'categories': [{'measurements': [{'value': '4.769', 'spread': '0.3966', 'groupId': 'OG000'}]}]}, {'title': 'Day 22', 'categories': [{'measurements': [{'value': '4.608', 'spread': '0.5308', 'groupId': 'OG000'}]}]}, {'title': 'Day 25', 'categories': [{'measurements': [{'value': '4.756', 'spread': '0.4718', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.', 'unitOfMeasure': '10^12 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Absolute Values of Erythrocytes Mean Corpuscular Volume', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Baseline (Day -1)', 'categories': [{'measurements': [{'value': '86.71', 'spread': '3.748', 'groupId': 'OG000'}]}]}, {'title': 'Day 10', 'categories': [{'measurements': [{'value': '88.02', 'spread': '3.938', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.', 'unitOfMeasure': 'Femtoliter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Absolute Values of Erythrocytes Mean Corpuscular Volume', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Baseline (Day 10)', 'categories': [{'measurements': [{'value': '88.02', 'spread': '3.938', 'groupId': 'OG000'}]}]}, {'title': 'Day 20', 'categories': [{'measurements': [{'value': '88.96', 'spread': '4.746', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.', 'unitOfMeasure': 'Femtoliter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Absolute Values of Erythrocytes Mean Corpuscular Volume', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Baseline (Day 20)', 'categories': [{'measurements': [{'value': '89.03', 'spread': '4.865', 'groupId': 'OG000'}]}]}, {'title': 'Day 22', 'categories': [{'measurements': [{'value': '87.38', 'spread': '4.217', 'groupId': 'OG000'}]}]}, {'title': 'Day 25', 'categories': [{'measurements': [{'value': '87.74', 'spread': '4.045', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.', 'unitOfMeasure': 'Femtoliter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Baseline (Day -1)', 'categories': [{'measurements': [{'value': '29.37', 'spread': '1.546', 'groupId': 'OG000'}]}]}, {'title': 'Day 10', 'categories': [{'measurements': [{'value': '29.57', 'spread': '1.667', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.', 'unitOfMeasure': 'Picograms', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Baseline (Day 10)', 'categories': [{'measurements': [{'value': '29.57', 'spread': '1.667', 'groupId': 'OG000'}]}]}, {'title': 'Day 20', 'categories': [{'measurements': [{'value': '29.52', 'spread': '1.602', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.', 'unitOfMeasure': 'Picograms', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Baseline (Day 20)', 'categories': [{'measurements': [{'value': '29.51', 'spread': '1.645', 'groupId': 'OG000'}]}]}, {'title': 'Day 22', 'categories': [{'measurements': [{'value': '29.28', 'spread': '1.670', 'groupId': 'OG000'}]}]}, {'title': 'Day 25', 'categories': [{'measurements': [{'value': '29.12', 'spread': '1.626', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.', 'unitOfMeasure': 'Picograms', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Baseline (Day -1): Glucose', 'categories': [{'measurements': [{'value': '5.0348', 'spread': '0.37437', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Glucose', 'categories': [{'measurements': [{'value': '4.8211', 'spread': '0.44125', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Carbon Dioxide', 'categories': [{'measurements': [{'value': '104.1', 'spread': '2.04', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Carbon Dioxide', 'categories': [{'measurements': [{'value': '25.4', 'spread': '2.11', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Cholesterol', 'categories': [{'measurements': [{'value': '4.4570', 'spread': '1.00121', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Cholesterol', 'categories': [{'measurements': [{'value': '3.8118', 'spread': '0.85065', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Triglycerides', 'categories': [{'measurements': [{'value': '1.2232', 'spread': '0.51018', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Triglycerides', 'categories': [{'measurements': [{'value': '1.1814', 'spread': '0.82178', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Anion Gap', 'categories': [{'measurements': [{'value': '7.9', 'spread': '1.80', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Anion Gap', 'categories': [{'measurements': [{'value': '13.8', 'spread': '1.71', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Calcium', 'categories': [{'measurements': [{'value': '2.3765', 'spread': '0.09976', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Calcium', 'categories': [{'measurements': [{'value': '2.3141', 'spread': '0.10267', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Chloride', 'categories': [{'measurements': [{'value': '25.8', 'spread': '2.10', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Chloride', 'categories': [{'measurements': [{'value': '103.7', 'spread': '1.81', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Phosphate', 'categories': [{'measurements': [{'value': '1.1075', 'spread': '0.16734', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Phosphate', 'categories': [{'measurements': [{'value': '1.1754', 'spread': '0.16141', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Potassium', 'categories': [{'measurements': [{'value': '4.48', 'spread': '0.339', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Potassium', 'categories': [{'measurements': [{'value': '4.43', 'spread': '0.256', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Sodium', 'categories': [{'measurements': [{'value': '137.7', 'spread': '2.00', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Sodium', 'categories': [{'measurements': [{'value': '138.4', 'spread': '1.93', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Urea', 'categories': [{'measurements': [{'value': '4.8195', 'spread': '0.78983', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Urea', 'categories': [{'measurements': [{'value': '5.9458', 'spread': '1.43309', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, urea. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.', 'unitOfMeasure': 'Millimoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Baseline (Day 10): Glucose', 'categories': [{'measurements': [{'value': '4.8211', 'spread': '0.44125', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Glucose', 'categories': [{'measurements': [{'value': '4.7378', 'spread': '0.45996', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Carbon Dioxide', 'categories': [{'measurements': [{'value': '25.4', 'spread': '2.11', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Carbon Dioxide', 'categories': [{'measurements': [{'value': '24.9', 'spread': '2.11', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Cholesterol', 'categories': [{'measurements': [{'value': '3.8118', 'spread': '0.85065', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Cholesterol', 'categories': [{'measurements': [{'value': '3.6915', 'spread': '0.94881', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Triglycerides', 'categories': [{'measurements': [{'value': '1.1814', 'spread': '0.82178', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Triglycerides', 'categories': [{'measurements': [{'value': '1.0825', 'spread': '0.84563', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Anion Gap', 'categories': [{'measurements': [{'value': '13.8', 'spread': '1.71', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Anion Gap', 'categories': [{'measurements': [{'value': '14.5', 'spread': '2.12', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Calcium', 'categories': [{'measurements': [{'value': '2.3141', 'spread': '0.10267', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Calcium', 'categories': [{'measurements': [{'value': '2.3141', 'spread': '0.08825', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Chloride', 'categories': [{'measurements': [{'value': '103.7', 'spread': '1.81', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Chloride', 'categories': [{'measurements': [{'value': '103.6', 'spread': '2.30', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Phosphate', 'categories': [{'measurements': [{'value': '1.1754', 'spread': '0.16141', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Phosphate', 'categories': [{'measurements': [{'value': '1.2593', 'spread': '0.13294', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Potassium', 'categories': [{'measurements': [{'value': '4.43', 'spread': '0.256', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Potassium', 'categories': [{'measurements': [{'value': '4.39', 'spread': '0.383', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Sodium', 'categories': [{'measurements': [{'value': '138.4', 'spread': '1.93', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Sodium', 'categories': [{'measurements': [{'value': '138.6', 'spread': '1.64', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Urea', 'categories': [{'measurements': [{'value': '5.9458', 'spread': '1.43309', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Urea', 'categories': [{'measurements': [{'value': '5.6335', 'spread': '1.72537', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, and urea. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.', 'unitOfMeasure': 'Millimoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Baseline (Day 20): Glucose', 'categories': [{'measurements': [{'value': '4.7184', 'spread': '0.46406', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Glucose', 'categories': [{'measurements': [{'value': '4.8060', 'spread': '0.37890', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Glucose', 'categories': [{'measurements': [{'value': '4.8703', 'spread': '0.40699', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Carbon Dioxide', 'categories': [{'measurements': [{'value': '24.9', 'spread': '2.12', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Carbon Dioxide', 'categories': [{'measurements': [{'value': '25.4', 'spread': '1.74', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Carbon Dioxide', 'categories': [{'measurements': [{'value': '26.2', 'spread': '1.80', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Cholesterol', 'categories': [{'measurements': [{'value': '3.6898', 'spread': '0.97478', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Cholesterol', 'categories': [{'measurements': [{'value': '3.2543', 'spread': '0.88216', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Cholesterol', 'categories': [{'measurements': [{'value': '3.3972', 'spread': '0.89603', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Triglycerides', 'categories': [{'measurements': [{'value': '1.0783', 'spread': '0.86858', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Triglycerides', 'categories': [{'measurements': [{'value': '1.0836', 'spread': '0.78925', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Triglycerides', 'categories': [{'measurements': [{'value': '1.1074', 'spread': '0.81372', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Anion Gap', 'categories': [{'measurements': [{'value': '14.6', 'spread': '2.14', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Anion Gap', 'categories': [{'measurements': [{'value': '13.9', 'spread': '1.27', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Anion Gap', 'categories': [{'measurements': [{'value': '14.5', 'spread': '1.95', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Calcium', 'categories': [{'measurements': [{'value': '2.3217', 'spread': '0.08377', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Calcium', 'categories': [{'measurements': [{'value': '2.2810', 'spread': '0.10822', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Calcium', 'categories': [{'measurements': [{'value': '2.3519', 'spread': '0.09440', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Chloride', 'categories': [{'measurements': [{'value': '103.4', 'spread': '2.22', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Chloride', 'categories': [{'measurements': [{'value': '104.8', 'spread': '2.02', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Chloride', 'categories': [{'measurements': [{'value': '102.6', 'spread': '1.86', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Phosphate', 'categories': [{'measurements': [{'value': '1.2661', 'spread': '0.13297', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Phosphate', 'categories': [{'measurements': [{'value': '1.1981', 'spread': '0.14871', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Phosphate', 'categories': [{'measurements': [{'value': '1.3477', 'spread': '0.18638', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Potassium', 'categories': [{'measurements': [{'value': '4.38', 'spread': '0.392', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Potassium', 'categories': [{'measurements': [{'value': '4.34', 'spread': '0.347', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Potassium', 'categories': [{'measurements': [{'value': '4.35', 'spread': '0.355', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Sodium', 'categories': [{'measurements': [{'value': '138.6', 'spread': '1.67', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Sodium', 'categories': [{'measurements': [{'value': '139.8', 'spread': '1.34', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Sodium', 'categories': [{'measurements': [{'value': '139.0', 'spread': '1.67', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Urea', 'categories': [{'measurements': [{'value': '5.7364', 'spread': '1.70835', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Urea', 'categories': [{'measurements': [{'value': '4.9078', 'spread': '1.44100', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Urea', 'categories': [{'measurements': [{'value': '5.3099', 'spread': '1.18355', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium and urea. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.', 'unitOfMeasure': 'Millimoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Baseline (Day -1): Urate', 'categories': [{'measurements': [{'value': '347.3632', 'spread': '69.50981', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Urate', 'categories': [{'measurements': [{'value': '365.5046', 'spread': '75.74195', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Creatinine', 'categories': [{'measurements': [{'value': '84.9524', 'spread': '19.89935', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Creatinine', 'categories': [{'measurements': [{'value': '86.4110', 'spread': '21.46247', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Bilirubin', 'categories': [{'measurements': [{'value': '9.8325', 'spread': '3.13227', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Bilirubin', 'categories': [{'measurements': [{'value': '8.0028', 'spread': '3.01005', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Direct bilirubin', 'categories': [{'measurements': [{'value': '2.0520', 'spread': '0.70177', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Direct bilirubin', 'categories': [{'measurements': [{'value': '1.7015', 'spread': '0.63856', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.', 'unitOfMeasure': 'Micromoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Baseline (Day 10): Urate', 'categories': [{'measurements': [{'value': '365.5046', 'spread': '75.74195', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Urate', 'categories': [{'measurements': [{'value': '337.8464', 'spread': '76.60060', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Creatinine', 'categories': [{'measurements': [{'value': '86.4110', 'spread': '21.46247', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Creatinine', 'categories': [{'measurements': [{'value': '90.7868', 'spread': '22.81174', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Bilirubin', 'categories': [{'measurements': [{'value': '8.0028', 'spread': '3.01005', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Bilirubin', 'categories': [{'measurements': [{'value': '8.6184', 'spread': '3.04856', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Direct bilirubin', 'categories': [{'measurements': [{'value': '1.7015', 'spread': '0.63856', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Direct bilirubin', 'categories': [{'measurements': [{'value': '1.8126', 'spread': '0.64557', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.', 'unitOfMeasure': 'Micromoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Baseline (Day 20): Urate', 'categories': [{'measurements': [{'value': '343.1057', 'spread': '74.89791', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Urate', 'categories': [{'measurements': [{'value': '303.0349', 'spread': '71.88291', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Urate', 'categories': [{'measurements': [{'value': '340.6013', 'spread': '67.89995', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Creatinine', 'categories': [{'measurements': [{'value': '92.1686', 'spread': '22.56047', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Creatinine', 'categories': [{'measurements': [{'value': '87.3764', 'spread': '22.63812', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Creatinine', 'categories': [{'measurements': [{'value': '90.5867', 'spread': '21.29029', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Bilirubin', 'categories': [{'measurements': [{'value': '8.7480', 'spread': '3.07497', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Bilirubin', 'categories': [{'measurements': [{'value': '9.8820', 'spread': '3.24579', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Bilirubin', 'categories': [{'measurements': [{'value': '9.0360', 'spread': '3.89534', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Direct bilirubin', 'categories': [{'measurements': [{'value': '1.8450', 'spread': '0.64634', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Direct bilirubin', 'categories': [{'measurements': [{'value': '2.0790', 'spread': '0.60930', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Direct bilirubin', 'categories': [{'measurements': [{'value': '1.9980', 'spread': '0.70286', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.', 'unitOfMeasure': 'Micromoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Absolute Values of Albumin, Globulin, Protein', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Baseline (Day -1): Albumin', 'categories': [{'measurements': [{'value': '42.9', 'spread': '2.95', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Albumin', 'categories': [{'measurements': [{'value': '42.2', 'spread': '3.14', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Globulin', 'categories': [{'measurements': [{'value': '27.4', 'spread': '3.14', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Globulin', 'categories': [{'measurements': [{'value': '25.9', 'spread': '3.04', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Protein', 'categories': [{'measurements': [{'value': '70.3', 'spread': '4.52', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Protein', 'categories': [{'measurements': [{'value': '68.1', 'spread': '3.77', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Absolute Values of Albumin, Globulin, Protein', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Baseline (Day 10): Albumin', 'categories': [{'measurements': [{'value': '42.2', 'spread': '3.14', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Albumin', 'categories': [{'measurements': [{'value': '41.4', 'spread': '3.31', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Globulin', 'categories': [{'measurements': [{'value': '25.9', 'spread': '3.04', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Globulin', 'categories': [{'measurements': [{'value': '26.8', 'spread': '3.58', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Protein', 'categories': [{'measurements': [{'value': '68.1', 'spread': '3.77', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Protein', 'categories': [{'measurements': [{'value': '68.2', 'spread': '4.93', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Absolute Values of Albumin, Globulin, Protein', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Baseline (Day 20): Albumin', 'categories': [{'measurements': [{'value': '41.6', 'spread': '3.24', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Albumin', 'categories': [{'measurements': [{'value': '40.5', 'spread': '3.82', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Albumin', 'categories': [{'measurements': [{'value': '42.0', 'spread': '3.04', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Globulin', 'categories': [{'measurements': [{'value': '26.9', 'spread': '3.65', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Globulin', 'categories': [{'measurements': [{'value': '25.1', 'spread': '3.69', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Globulin', 'categories': [{'measurements': [{'value': '26.6', 'spread': '3.67', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Protein', 'categories': [{'measurements': [{'value': '68.5', 'spread': '4.85', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Protein', 'categories': [{'measurements': [{'value': '65.6', 'spread': '5.74', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Protein', 'categories': [{'measurements': [{'value': '68.6', 'spread': '4.34', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Baseline (Day -1): Creatine kinase', 'categories': [{'measurements': [{'value': '103.7', 'spread': '79.68', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Creatine kinase', 'categories': [{'measurements': [{'value': '66.9', 'spread': '34.67', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Lactate dehydrogenase', 'categories': [{'measurements': [{'value': '131.3', 'spread': '19.59', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Lactate dehydrogenase', 'categories': [{'measurements': [{'value': '114.8', 'spread': '16.87', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): ALT', 'categories': [{'measurements': [{'value': '15.6', 'spread': '7.66', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: ALT', 'categories': [{'measurements': [{'value': '20.1', 'spread': '14.66', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): ALP', 'categories': [{'measurements': [{'value': '62.7', 'spread': '18.46', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: ALP', 'categories': [{'measurements': [{'value': '60.8', 'spread': '18.03', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): AST', 'categories': [{'measurements': [{'value': '14.6', 'spread': '3.89', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: AST', 'categories': [{'measurements': [{'value': '15.6', 'spread': '5.32', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Gamma-glutamyl transferase', 'categories': [{'measurements': [{'value': '19.1', 'spread': '7.16', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Gamma-glutamyl transferase', 'categories': [{'measurements': [{'value': '18.9', 'spread': '8.10', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.', 'unitOfMeasure': 'International units per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Baseline (Day 10): Creatine kinase', 'categories': [{'measurements': [{'value': '66.9', 'spread': '34.67', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Creatine kinase', 'categories': [{'measurements': [{'value': '68.9', 'spread': '47.98', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Lactate dehydrogenase', 'categories': [{'measurements': [{'value': '114.8', 'spread': '16.87', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Lactate dehydrogenase', 'categories': [{'measurements': [{'value': '115.9', 'spread': '17.00', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): ALT', 'categories': [{'measurements': [{'value': '20.1', 'spread': '14.66', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: ALT', 'categories': [{'measurements': [{'value': '20.3', 'spread': '12.38', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): ALP', 'categories': [{'measurements': [{'value': '60.8', 'spread': '18.03', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: ALP', 'categories': [{'measurements': [{'value': '58.5', 'spread': '15.56', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): AST', 'categories': [{'measurements': [{'value': '15.6', 'spread': '5.32', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: AST', 'categories': [{'measurements': [{'value': '16.1', 'spread': '4.80', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Gamma-glutamyl transferase', 'categories': [{'measurements': [{'value': '18.9', 'spread': '8.10', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Gamma-glutamyl transferase', 'categories': [{'measurements': [{'value': '18.3', 'spread': '7.69', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, and gamma-glutamyl transferase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.', 'unitOfMeasure': 'International units per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Baseline (Day 20): Creatine kinase', 'categories': [{'measurements': [{'value': '71.3', 'spread': '48.03', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Creatine kinase', 'categories': [{'measurements': [{'value': '65.7', 'spread': '34.56', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Creatine kinase', 'categories': [{'measurements': [{'value': '63.8', 'spread': '30.90', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Lactate dehydrogenase', 'categories': [{'measurements': [{'value': '116.6', 'spread': '17.13', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Lactate dehydrogenase', 'categories': [{'measurements': [{'value': '120.6', 'spread': '23.62', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Lactate dehydrogenase', 'categories': [{'measurements': [{'value': '119.3', 'spread': '19.18', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): ALT', 'categories': [{'measurements': [{'value': '20.4', 'spread': '12.70', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: ALT', 'categories': [{'measurements': [{'value': '17.3', 'spread': '9.36', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: ALT', 'categories': [{'measurements': [{'value': '20.9', 'spread': '11.92', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): ALP', 'categories': [{'measurements': [{'value': '58.5', 'spread': '15.98', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: ALP', 'categories': [{'measurements': [{'value': '57.6', 'spread': '16.26', 'groupId': 'OG000'}]}]}, {'title': 'Day 25:ALP', 'categories': [{'measurements': [{'value': '58.6', 'spread': '16.40', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): AST', 'categories': [{'measurements': [{'value': '16.2', 'spread': '4.91', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: AST', 'categories': [{'measurements': [{'value': '14.7', 'spread': '3.78', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: AST', 'categories': [{'measurements': [{'value': '16.4', 'spread': '4.56', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Gamma-glutamyl transferase', 'categories': [{'measurements': [{'value': '18.5', 'spread': '7.83', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Gamma-glutamyl transferase', 'categories': [{'measurements': [{'value': '17.1', 'spread': '6.77', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Gamma-glutamyl transferase', 'categories': [{'measurements': [{'value': '18.7', 'spread': '8.23', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, gamma-glutamyl transferase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.', 'unitOfMeasure': 'International units per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Absolute Values of Amylase, Lipase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Baseline (Day -1): Lipase', 'categories': [{'measurements': [{'value': '29.4', 'spread': '14.73', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Lipase', 'categories': [{'measurements': [{'value': '31.6', 'spread': '11.99', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day -1): Amylase', 'categories': [{'measurements': [{'value': '59.5', 'spread': '22.37', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: Amylase', 'categories': [{'measurements': [{'value': '56.9', 'spread': '20.93', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.', 'unitOfMeasure': 'Units per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Absolute Values of Amylase, Lipase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Baseline (Day 10): Lipase', 'categories': [{'measurements': [{'value': '31.6', 'spread': '11.99', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Lipase', 'categories': [{'measurements': [{'value': '32.4', 'spread': '14.51', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 10): Amylase', 'categories': [{'measurements': [{'value': '56.9', 'spread': '20.93', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: Amylase', 'categories': [{'measurements': [{'value': '60.1', 'spread': '23.22', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.', 'unitOfMeasure': 'Units per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Absolute Values of Amylase, Lipase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Baseline (Day 20): Lipase', 'categories': [{'measurements': [{'value': '32.9', 'spread': '14.74', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Lipase', 'categories': [{'measurements': [{'value': '33.5', 'spread': '15.19', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Lipase', 'categories': [{'measurements': [{'value': '33.1', 'spread': '14.58', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 20): Amylase', 'categories': [{'measurements': [{'value': '62.2', 'spread': '21.79', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Amylase', 'categories': [{'measurements': [{'value': '64.7', 'spread': '25.32', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Amylase', 'categories': [{'measurements': [{'value': '60.7', 'spread': '21.08', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.', 'unitOfMeasure': 'Units per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Platelet count', 'categories': [{'measurements': [{'value': '7.3', 'spread': '20.01', 'groupId': 'OG000'}]}]}, {'title': 'Leukocyte count', 'categories': [{'measurements': [{'value': '0.66', 'spread': '0.844', 'groupId': 'OG000'}]}]}, {'title': 'Neutrophils', 'categories': [{'measurements': [{'value': '0.5926', 'spread': '0.68577', 'groupId': 'OG000'}]}]}, {'title': 'Lymphocytes', 'categories': [{'measurements': [{'value': '0.0748', 'spread': '0.25872', 'groupId': 'OG000'}]}]}, {'title': 'Monocytes', 'categories': [{'measurements': [{'value': '-0.0375', 'spread': '0.09379', 'groupId': 'OG000'}]}]}, {'title': 'Eosinophils', 'categories': [{'measurements': [{'value': '0.0150', 'spread': '0.07023', 'groupId': 'OG000'}]}]}, {'title': 'Basophils', 'categories': [{'measurements': [{'value': '0.0110', 'spread': '0.02138', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': '10^9 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Platelet count', 'categories': [{'measurements': [{'value': '-4.1', 'spread': '17.31', 'groupId': 'OG000'}]}]}, {'title': 'Leukocyte count', 'categories': [{'measurements': [{'value': '-0.51', 'spread': '0.947', 'groupId': 'OG000'}]}]}, {'title': 'Neutrophils', 'categories': [{'measurements': [{'value': '-0.4750', 'spread': '0.63752', 'groupId': 'OG000'}]}]}, {'title': 'Lymphocytes', 'categories': [{'measurements': [{'value': '-0.0610', 'spread': '0.39045', 'groupId': 'OG000'}]}]}, {'title': 'Monocytes', 'categories': [{'measurements': [{'value': '-0.0080', 'spread': '0.11134', 'groupId': 'OG000'}]}]}, {'title': 'Eosinophils', 'categories': [{'measurements': [{'value': '0.0310', 'spread': '0.10686', 'groupId': 'OG000'}]}]}, {'title': 'Basophils', 'categories': [{'measurements': [{'value': '0.0020', 'spread': '0.02526', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': '10^9 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Day 22: Platelet count', 'categories': [{'measurements': [{'value': '-13.1', 'spread': '19.31', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Platelet count', 'categories': [{'measurements': [{'value': '-1.6', 'spread': '24.62', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Leukocyte count', 'categories': [{'measurements': [{'value': '-0.05', 'spread': '0.906', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Leukocyte count', 'categories': [{'measurements': [{'value': '0.12', 'spread': '0.820', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Neutrophils', 'categories': [{'measurements': [{'value': '-0.1254', 'spread': '0.74916', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Neutrophils', 'categories': [{'measurements': [{'value': '0.1351', 'spread': '0.72701', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Lymphocytes', 'categories': [{'measurements': [{'value': '0.0351', 'spread': '0.42962', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Lymphocytes', 'categories': [{'measurements': [{'value': '0.0843', 'spread': '0.41536', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Monocytes', 'categories': [{'measurements': [{'value': '0.0184', 'spread': '0.08808', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Monocytes', 'categories': [{'measurements': [{'value': '-0.0929', 'spread': '0.17694', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Eosinophils', 'categories': [{'measurements': [{'value': '0.0329', 'spread': '0.12007', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Eosinophils', 'categories': [{'measurements': [{'value': '-0.0115', 'spread': '0.06076', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Basophils', 'categories': [{'measurements': [{'value': '-0.0094', 'spread': '0.03787', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Basophils', 'categories': [{'measurements': [{'value': '-0.0066', 'spread': '0.03173', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': '10^9 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Change From Baseline in Hematocrit', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.0090', 'spread': '0.02082', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Proportion of red blood cells in blood', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Change From Baseline in Hematocrit', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.0118', 'spread': '0.01667', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Proportion of red blood cells in blood', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Change From Baseline in Hematocrit', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Day 22', 'categories': [{'measurements': [{'value': '-0.0217', 'spread': '0.02090', 'groupId': 'OG000'}]}]}, {'title': 'Day 25', 'categories': [{'measurements': [{'value': '-0.0071', 'spread': '0.02129', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Proportion of red blood cells in blood', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Change From Baseline in Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'categories': [{'measurements': [{'value': '-4.2', 'spread': '6.34', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Change From Baseline in Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.3', 'spread': '4.91', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Change From Baseline in Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Day 22', 'categories': [{'measurements': [{'value': '-5.8', 'spread': '6.52', 'groupId': 'OG000'}]}]}, {'title': 'Day 25', 'categories': [{'measurements': [{'value': '-2.3', 'spread': '5.82', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Change From Baseline in Erythrocytes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.172', 'spread': '0.2219', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': '10^12 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Change From Baseline in Erythrocytes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.083', 'spread': '0.1768', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': '10^12 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Change From Baseline in Erythrocytes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Day 22', 'categories': [{'measurements': [{'value': '-0.161', 'spread': '0.2190', 'groupId': 'OG000'}]}]}, {'title': 'Day 25', 'categories': [{'measurements': [{'value': '-0.013', 'spread': '0.2027', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': '10^12 cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Change From Baseline in Erythrocytes Mean Corpuscular Volume', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.31', 'spread': '1.539', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Femtoliter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Change From Baseline in Erythrocytes Mean Corpuscular Volume', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.94', 'spread': '2.519', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Femtoliter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Change From Baseline in Erythrocytes Mean Corpuscular Volume', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Day 22', 'categories': [{'measurements': [{'value': '-1.64', 'spread': '1.849', 'groupId': 'OG000'}]}]}, {'title': 'Day 25', 'categories': [{'measurements': [{'value': '-1.28', 'spread': '2.234', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Femtoliter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.20', 'spread': '0.352', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Picograms', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.05', 'spread': '0.298', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Picograms', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Day 22', 'categories': [{'measurements': [{'value': '-0.23', 'spread': '0.407', 'groupId': 'OG000'}]}]}, {'title': 'Day 25', 'categories': [{'measurements': [{'value': '-0.39', 'spread': '0.519', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Picograms', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Glucose', 'categories': [{'measurements': [{'value': '-0.2137', 'spread': '0.29663', 'groupId': 'OG000'}]}]}, {'title': 'Carbon Dioxide', 'categories': [{'measurements': [{'value': '-78.7', 'spread': '3.12', 'groupId': 'OG000'}]}]}, {'title': 'Cholesterol', 'categories': [{'measurements': [{'value': '-0.6452', 'spread': '0.47501', 'groupId': 'OG000'}]}]}, {'title': 'Triglycerides', 'categories': [{'measurements': [{'value': '-0.0418', 'spread': '0.59458', 'groupId': 'OG000'}]}]}, {'title': 'Anion Gap', 'categories': [{'measurements': [{'value': '5.9', 'spread': '2.21', 'groupId': 'OG000'}]}]}, {'title': 'Calcium', 'categories': [{'measurements': [{'value': '-0.0624', 'spread': '0.04889', 'groupId': 'OG000'}]}]}, {'title': 'Chloride', 'categories': [{'measurements': [{'value': '78.0', 'spread': '2.98', 'groupId': 'OG000'}]}]}, {'title': 'Phosphate', 'categories': [{'measurements': [{'value': '0.0678', 'spread': '0.10522', 'groupId': 'OG000'}]}]}, {'title': 'Potassium', 'categories': [{'measurements': [{'value': '-0.05', 'spread': '0.402', 'groupId': 'OG000'}]}]}, {'title': 'Sodium', 'categories': [{'measurements': [{'value': '0.7', 'spread': '2.16', 'groupId': 'OG000'}]}]}, {'title': 'Urea', 'categories': [{'measurements': [{'value': '1.1263', 'spread': '0.97483', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, and urea. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Millimoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Glucose', 'categories': [{'measurements': [{'value': '-0.0833', 'spread': '0.29345', 'groupId': 'OG000'}]}]}, {'title': 'Carbon Dioxide', 'categories': [{'measurements': [{'value': '-0.6', 'spread': '1.79', 'groupId': 'OG000'}]}]}, {'title': 'Cholesterol', 'categories': [{'measurements': [{'value': '-0.1203', 'spread': '0.30774', 'groupId': 'OG000'}]}]}, {'title': 'Triglycerides', 'categories': [{'measurements': [{'value': '-0.0989', 'spread': '0.30531', 'groupId': 'OG000'}]}]}, {'title': 'Anion Gap', 'categories': [{'measurements': [{'value': '0.8', 'spread': '1.94', 'groupId': 'OG000'}]}]}, {'title': 'Calcium', 'categories': [{'measurements': [{'value': '0.0000', 'spread': '0.06575', 'groupId': 'OG000'}]}]}, {'title': 'Chloride', 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.52', 'groupId': 'OG000'}]}]}, {'title': 'Phosphate', 'categories': [{'measurements': [{'value': '0.0840', 'spread': '0.08601', 'groupId': 'OG000'}]}]}, {'title': 'Potassium', 'categories': [{'measurements': [{'value': '-0.05', 'spread': '0.378', 'groupId': 'OG000'}]}]}, {'title': 'Sodium', 'categories': [{'measurements': [{'value': '0.3', 'spread': '1.41', 'groupId': 'OG000'}]}]}, {'title': 'Urea', 'categories': [{'measurements': [{'value': '-0.3124', 'spread': '0.72202', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, and urea. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Millimoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Day 22: Glucose', 'categories': [{'measurements': [{'value': '0.0876', 'spread': '0.29392', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Glucose', 'categories': [{'measurements': [{'value': '0.1519', 'spread': '0.32570', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Carbon Dioxide', 'categories': [{'measurements': [{'value': '0.5', 'spread': '2.12', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Carbon Dioxide', 'categories': [{'measurements': [{'value': '1.2', 'spread': '1.81', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Cholesterol', 'categories': [{'measurements': [{'value': '-0.4355', 'spread': '0.31287', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Cholesterol', 'categories': [{'measurements': [{'value': '-0.2926', 'spread': '0.25147', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Triglycerides', 'categories': [{'measurements': [{'value': '0.0054', 'spread': '0.14595', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Triglycerides', 'categories': [{'measurements': [{'value': '0.0291', 'spread': '0.18280', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Anion Gap', 'categories': [{'measurements': [{'value': '-0.6', 'spread': '1.80', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Anion Gap', 'categories': [{'measurements': [{'value': '-0.1', 'spread': '0.97', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Calcium', 'categories': [{'measurements': [{'value': '-0.0407', 'spread': '0.07165', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Calcium', 'categories': [{'measurements': [{'value': '0.0302', 'spread': '0.05553', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Chloride', 'categories': [{'measurements': [{'value': '1.4', 'spread': '1.64', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Chloride', 'categories': [{'measurements': [{'value': '-0.8', 'spread': '1.78', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Phosphate', 'categories': [{'measurements': [{'value': '-0.0680', 'spread': '0.09860', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Phosphate', 'categories': [{'measurements': [{'value': '0.0816', 'spread': '0.09527', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Potassium', 'categories': [{'measurements': [{'value': '-0.04', 'spread': '0.373', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Potassium', 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.441', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Sodium', 'categories': [{'measurements': [{'value': '1.2', 'spread': '1.51', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Sodium', 'categories': [{'measurements': [{'value': '0.4', 'spread': '2.41', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Urea', 'categories': [{'measurements': [{'value': '-0.8286', 'spread': '0.88169', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Urea', 'categories': [{'measurements': [{'value': '-0.4265', 'spread': '0.85981', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium and urea. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Millimoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Urate', 'categories': [{'measurements': [{'value': '18.1414', 'spread': '39.28786', 'groupId': 'OG000'}]}]}, {'title': 'Creatinine', 'categories': [{'measurements': [{'value': '1.4586', 'spread': '5.65145', 'groupId': 'OG000'}]}]}, {'title': 'Bilirubin', 'categories': [{'measurements': [{'value': '-1.8297', 'spread': '1.38266', 'groupId': 'OG000'}]}]}, {'title': 'Direct bilirubin', 'categories': [{'measurements': [{'value': '-0.3506', 'spread': '0.60895', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Micromoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Urate', 'categories': [{'measurements': [{'value': '-27.6582', 'spread': '25.47573', 'groupId': 'OG000'}]}]}, {'title': 'Creatinine', 'categories': [{'measurements': [{'value': '4.3758', 'spread': '4.38239', 'groupId': 'OG000'}]}]}, {'title': 'Bilirubin', 'categories': [{'measurements': [{'value': '0.6156', 'spread': '1.92059', 'groupId': 'OG000'}]}]}, {'title': 'Direct bilirubin', 'categories': [{'measurements': [{'value': '0.1112', 'spread': '0.46509', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Micromoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Day 22: Urate', 'categories': [{'measurements': [{'value': '-40.0707', 'spread': '26.51457', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Urate', 'categories': [{'measurements': [{'value': '-2.5044', 'spread': '26.62359', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Creatinine', 'categories': [{'measurements': [{'value': '-4.7922', 'spread': '5.82901', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Creatinine', 'categories': [{'measurements': [{'value': '-1.5819', 'spread': '4.60830', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Bilirubin', 'categories': [{'measurements': [{'value': '1.1340', 'spread': '1.91202', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Bilirubin', 'categories': [{'measurements': [{'value': '0.2880', 'spread': '2.14494', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Direct bilirubin', 'categories': [{'measurements': [{'value': '0.2340', 'spread': '0.38326', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Direct bilirubin', 'categories': [{'measurements': [{'value': '0.1530', 'spread': '0.39447', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Micromoles per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Change From Baseline in Albumin, Globulin, Protein', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Albumin', 'categories': [{'measurements': [{'value': '-0.7', 'spread': '1.75', 'groupId': 'OG000'}]}]}, {'title': 'Globulin', 'categories': [{'measurements': [{'value': '-1.5', 'spread': '1.61', 'groupId': 'OG000'}]}]}, {'title': 'Protein', 'categories': [{'measurements': [{'value': '-2.2', 'spread': '2.57', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Change From Baseline in Albumin, Globulin, Protein', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Albumin', 'categories': [{'measurements': [{'value': '-0.9', 'spread': '2.43', 'groupId': 'OG000'}]}]}, {'title': 'Globulin', 'categories': [{'measurements': [{'value': '0.9', 'spread': '2.07', 'groupId': 'OG000'}]}]}, {'title': 'Protein', 'categories': [{'measurements': [{'value': '0.1', 'spread': '3.71', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Change From Baseline in Albumin, Globulin, Protein', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Day 22: Albumin', 'categories': [{'measurements': [{'value': '-1.1', 'spread': '2.44', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Albumin', 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.71', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Globulin', 'categories': [{'measurements': [{'value': '-1.8', 'spread': '1.98', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Globulin', 'categories': [{'measurements': [{'value': '-0.3', 'spread': '1.76', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Protein', 'categories': [{'measurements': [{'value': '-2.9', 'spread': '4.15', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Protein', 'categories': [{'measurements': [{'value': '0.2', 'spread': '2.81', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Grams per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Creatine kinase', 'categories': [{'measurements': [{'value': '-36.9', 'spread': '59.38', 'groupId': 'OG000'}]}]}, {'title': 'Lactate dehydrogenase', 'categories': [{'measurements': [{'value': '-16.5', 'spread': '15.50', 'groupId': 'OG000'}]}]}, {'title': 'ALT', 'categories': [{'measurements': [{'value': '4.5', 'spread': '11.51', 'groupId': 'OG000'}]}]}, {'title': 'ALP', 'categories': [{'measurements': [{'value': '-1.9', 'spread': '6.39', 'groupId': 'OG000'}]}]}, {'title': 'AST', 'categories': [{'measurements': [{'value': '1.0', 'spread': '4.52', 'groupId': 'OG000'}]}]}, {'title': 'Gamma-glutamyl transferase', 'categories': [{'measurements': [{'value': '-0.2', 'spread': '3.86', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'International units per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Creatine kinase', 'categories': [{'measurements': [{'value': '2.1', 'spread': '24.48', 'groupId': 'OG000'}]}]}, {'title': 'Lactate dehydrogenase', 'categories': [{'measurements': [{'value': '1.1', 'spread': '13.15', 'groupId': 'OG000'}]}]}, {'title': 'ALT', 'categories': [{'measurements': [{'value': '0.3', 'spread': '6.78', 'groupId': 'OG000'}]}]}, {'title': 'ALP', 'categories': [{'measurements': [{'value': '-2.4', 'spread': '6.21', 'groupId': 'OG000'}]}]}, {'title': 'AST', 'categories': [{'measurements': [{'value': '0.6', 'spread': '3.03', 'groupId': 'OG000'}]}]}, {'title': 'Gamma-glutamyl transferase', 'categories': [{'measurements': [{'value': '-0.6', 'spread': '2.74', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, and gamma-glutamyl transferase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'International units per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Day 22: Creatine kinase', 'categories': [{'measurements': [{'value': '-5.6', 'spread': '21.78', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Creatine kinase', 'categories': [{'measurements': [{'value': '-7.5', 'spread': '26.10', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Lactate dehydrogenase', 'categories': [{'measurements': [{'value': '4.0', 'spread': '18.94', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Lactate dehydrogenase', 'categories': [{'measurements': [{'value': '2.6', 'spread': '16.30', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: ALT', 'categories': [{'measurements': [{'value': '-3.1', 'spread': '4.12', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: ALT', 'categories': [{'measurements': [{'value': '0.5', 'spread': '2.61', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: ALP', 'categories': [{'measurements': [{'value': '-0.9', 'spread': '5.83', 'groupId': 'OG000'}]}]}, {'title': 'Day 25:ALP', 'categories': [{'measurements': [{'value': '0.1', 'spread': '3.91', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: AST', 'categories': [{'measurements': [{'value': '-1.5', 'spread': '2.78', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: AST', 'categories': [{'measurements': [{'value': '0.2', 'spread': '1.89', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Gamma-glutamyl transferase', 'categories': [{'measurements': [{'value': '-1.5', 'spread': '1.61', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Gamma-glutamyl transferase', 'categories': [{'measurements': [{'value': '0.2', 'spread': '1.26', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, gamma-glutamyl transferase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'International units per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Change From Baseline in Amylase, Lipase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Lipase', 'categories': [{'measurements': [{'value': '2.2', 'spread': '6.81', 'groupId': 'OG000'}]}]}, {'title': 'Amylase', 'categories': [{'measurements': [{'value': '-2.6', 'spread': '7.86', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Units per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Change From Baseline in Amylase, Lipase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Lipase', 'categories': [{'measurements': [{'value': '0.9', 'spread': '6.07', 'groupId': 'OG000'}]}]}, {'title': 'Amylase', 'categories': [{'measurements': [{'value': '3.2', 'spread': '6.31', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Units per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Change From Baseline in Amylase, Lipase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Day 22: Lipase', 'categories': [{'measurements': [{'value': '0.6', 'spread': '10.08', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Lipase', 'categories': [{'measurements': [{'value': '0.2', 'spread': '4.88', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: Amylase', 'categories': [{'measurements': [{'value': '2.5', 'spread': '7.10', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: Amylase', 'categories': [{'measurements': [{'value': '-1.5', 'spread': '4.98', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Units per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': "Treatment A: Absolute Values for Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Fridericia's Formula (QTcF)", 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Baseline (Day 1, Pre-dose): PR Interval', 'categories': [{'measurements': [{'value': '154.8', 'spread': '20.92', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: PR Interval', 'categories': [{'measurements': [{'value': '158.2', 'spread': '22.67', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 1, Pre-dose): QRS Duration', 'categories': [{'measurements': [{'value': '92.5', 'spread': '8.34', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: QRS Duration', 'categories': [{'measurements': [{'value': '95.0', 'spread': '10.11', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 1, Pre-dose): QT Interval', 'categories': [{'measurements': [{'value': '391.2', 'spread': '22.41', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: QT Interval', 'categories': [{'measurements': [{'value': '398.3', 'spread': '22.19', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 1, Pre-dose): QTcF Interval', 'categories': [{'measurements': [{'value': '401.0', 'spread': '16.48', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: QTcF Interval', 'categories': [{'measurements': [{'value': '405.8', 'spread': '16.25', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, Pre-Dose) and Day 10', 'description': 'Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.', 'unitOfMeasure': 'Milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Baseline (Day 11, Pre-dose): PR Interval', 'categories': [{'measurements': [{'value': '158.6', 'spread': '19.44', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: PR Interval', 'categories': [{'measurements': [{'value': '161.8', 'spread': '22.40', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 11, Pre-dose): QRS Duration', 'categories': [{'measurements': [{'value': '94.2', 'spread': '8.73', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: QRS Duration', 'categories': [{'measurements': [{'value': '96.4', 'spread': '9.25', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 11, Pre-dose): QT Interval', 'categories': [{'measurements': [{'value': '403.1', 'spread': '26.27', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: QT Interval', 'categories': [{'measurements': [{'value': '408.8', 'spread': '25.85', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 11, Pre-dose): QTcF Interval', 'categories': [{'measurements': [{'value': '403.5', 'spread': '17.63', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: QTcF Interval', 'categories': [{'measurements': [{'value': '408.6', 'spread': '17.26', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.', 'unitOfMeasure': 'Milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Baseline (Day 21, Pre-dose): PR Interval', 'categories': [{'measurements': [{'value': '160.8', 'spread': '20.26', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: PR Interval', 'categories': [{'measurements': [{'value': '162.3', 'spread': '22.07', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: PR Interval', 'categories': [{'measurements': [{'value': '159.6', 'spread': '23.55', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 21, Pre-dose): QRS Duration', 'categories': [{'measurements': [{'value': '95.8', 'spread': '9.49', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: QRS Duration', 'categories': [{'measurements': [{'value': '98.7', 'spread': '10.30', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: QRS Duration', 'categories': [{'measurements': [{'value': '96.8', 'spread': '8.42', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 21, Pre-dose): QT Interval', 'categories': [{'measurements': [{'value': '402.6', 'spread': '21.06', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: QT Interval', 'categories': [{'measurements': [{'value': '420.6', 'spread': '21.16', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: QT Interval', 'categories': [{'measurements': [{'value': '398.7', 'spread': '22.25', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 21, Pre-dose): QTcF Interval', 'categories': [{'measurements': [{'value': '408.7', 'spread': '16.31', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: QTcF Interval', 'categories': [{'measurements': [{'value': '407.3', 'spread': '13.75', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: QTcF Interval', 'categories': [{'measurements': [{'value': '402.5', 'spread': '17.03', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.', 'unitOfMeasure': 'Milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'PR Interval', 'categories': [{'measurements': [{'value': '3.4', 'spread': '9.28', 'groupId': 'OG000'}]}]}, {'title': 'QRS Duration', 'categories': [{'measurements': [{'value': '2.5', 'spread': '4.37', 'groupId': 'OG000'}]}]}, {'title': 'QT Interval', 'categories': [{'measurements': [{'value': '7.1', 'spread': '12.81', 'groupId': 'OG000'}]}]}, {'title': 'QTcF Interval', 'categories': [{'measurements': [{'value': '4.8', 'spread': '9.27', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, Pre-dose) and Day 10', 'description': 'Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'PR Interval', 'categories': [{'measurements': [{'value': '3.2', 'spread': '8.79', 'groupId': 'OG000'}]}]}, {'title': 'QRS Duration', 'categories': [{'measurements': [{'value': '2.3', 'spread': '2.77', 'groupId': 'OG000'}]}]}, {'title': 'QT Interval', 'categories': [{'measurements': [{'value': '5.7', 'spread': '13.30', 'groupId': 'OG000'}]}]}, {'title': 'QTcF Interval', 'categories': [{'measurements': [{'value': '5.1', 'spread': '10.69', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Day 22: PR Interval', 'categories': [{'measurements': [{'value': '1.5', 'spread': '9.99', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: PR Interval', 'categories': [{'measurements': [{'value': '-1.2', 'spread': '10.07', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: QRS Duration', 'categories': [{'measurements': [{'value': '2.9', 'spread': '4.24', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: QRS Duration', 'categories': [{'measurements': [{'value': '1.0', 'spread': '3.43', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: QT Interval', 'categories': [{'measurements': [{'value': '18.0', 'spread': '20.32', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: QT Interval', 'categories': [{'measurements': [{'value': '-3.9', 'spread': '16.18', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: QTcF Interval', 'categories': [{'measurements': [{'value': '-1.4', 'spread': '9.44', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: QTcF Interval', 'categories': [{'measurements': [{'value': '-6.3', 'spread': '8.41', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Absolute Values of Oral Temperature', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Baseline (Day 1, Pre-dose)', 'categories': [{'measurements': [{'value': '36.38', 'spread': '0.293', 'groupId': 'OG000'}]}]}, {'title': 'Day 10', 'categories': [{'measurements': [{'value': '36.26', 'spread': '0.252', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, Pre-dose) and Day 10', 'description': 'Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.', 'unitOfMeasure': 'Degrees Celsius', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Absolute Values of Oral Temperature', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Baseline (Day 11, Pre-dose)', 'categories': [{'measurements': [{'value': '36.31', 'spread': '0.320', 'groupId': 'OG000'}]}]}, {'title': 'Day 20', 'categories': [{'measurements': [{'value': '36.28', 'spread': '0.246', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.', 'unitOfMeasure': 'Degrees Celsius', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Absolute Values of Oral Temperature', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Baseline (Day 21, Pre-dose)', 'categories': [{'measurements': [{'value': '36.31', 'spread': '0.284', 'groupId': 'OG000'}]}]}, {'title': 'Day 22', 'categories': [{'measurements': [{'value': '36.18', 'spread': '0.210', 'groupId': 'OG000'}]}]}, {'title': 'Day 25', 'categories': [{'measurements': [{'value': '36.31', 'spread': '0.300', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.', 'unitOfMeasure': 'Degrees Celsius', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Absolute Values of Pulse Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Baseline (Day 1, Pre-dose)', 'categories': [{'measurements': [{'value': '64.5', 'spread': '8.97', 'groupId': 'OG000'}]}]}, {'title': 'Day 10', 'categories': [{'measurements': [{'value': '65.0', 'spread': '8.19', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, Pre-dose) and Day 10', 'description': 'Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.', 'unitOfMeasure': 'Beats per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Absolute Values of Pulse Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Baseline (Day 11, Pre-dose)', 'categories': [{'measurements': [{'value': '61.6', 'spread': '9.95', 'groupId': 'OG000'}]}]}, {'title': 'Day 20', 'categories': [{'measurements': [{'value': '62.8', 'spread': '10.22', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.', 'unitOfMeasure': 'Beats per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Absolute Values of Pulse Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Baseline (Day 21, Pre-dose)', 'categories': [{'measurements': [{'value': '63.2', 'spread': '7.04', 'groupId': 'OG000'}]}]}, {'title': 'Day 22', 'categories': [{'measurements': [{'value': '56.2', 'spread': '6.83', 'groupId': 'OG000'}]}]}, {'title': 'Day 25', 'categories': [{'measurements': [{'value': '61.7', 'spread': '7.27', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.', 'unitOfMeasure': 'Beats per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Absolute Values of Respiratory Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Baseline (Day 1, Pre-dose)', 'categories': [{'measurements': [{'value': '16.1', 'spread': '1.37', 'groupId': 'OG000'}]}]}, {'title': 'Day 2', 'categories': [{'measurements': [{'value': '15.8', 'spread': '2.33', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, Pre-dose) and Day 2', 'description': 'Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.', 'unitOfMeasure': 'Breaths per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Absolute Values of Respiratory Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Baseline (Day 11, Pre-dose)', 'categories': [{'measurements': [{'value': '15.0', 'spread': '2.29', 'groupId': 'OG000'}]}]}, {'title': 'Day 20', 'categories': [{'measurements': [{'value': '14.7', 'spread': '2.27', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.', 'unitOfMeasure': 'Breaths per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Absolute Values of Respiratory Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Baseline (Day 21, Pre-dose)', 'categories': [{'measurements': [{'value': '15.7', 'spread': '1.56', 'groupId': 'OG000'}]}]}, {'title': 'Day 22', 'categories': [{'measurements': [{'value': '15.7', 'spread': '1.38', 'groupId': 'OG000'}]}]}, {'title': 'Day 25', 'categories': [{'measurements': [{'value': '16.5', 'spread': '2.20', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.', 'unitOfMeasure': 'Breaths per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Absolute Values of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'Baseline (Day 1, Pre-dose): SBP', 'categories': [{'measurements': [{'value': '111.0', 'spread': '9.03', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: SBP', 'categories': [{'measurements': [{'value': '107.7', 'spread': '9.32', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 1, Pre-dose): DBP', 'categories': [{'measurements': [{'value': '65.1', 'spread': '6.73', 'groupId': 'OG000'}]}]}, {'title': 'Day 10: DBP', 'categories': [{'measurements': [{'value': '59.7', 'spread': '6.24', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, Pre-dose) and Day 10', 'description': 'SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.', 'unitOfMeasure': 'Millimeters of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Absolute Values of SBP and DBP', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'Baseline (Day 11, Pre-dose): SBP', 'categories': [{'measurements': [{'value': '107.7', 'spread': '8.46', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: SBP', 'categories': [{'measurements': [{'value': '107.2', 'spread': '9.52', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 11, Pre-dose): DBP', 'categories': [{'measurements': [{'value': '61.6', 'spread': '6.56', 'groupId': 'OG000'}]}]}, {'title': 'Day 20: DBP', 'categories': [{'measurements': [{'value': '59.6', 'spread': '5.55', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.', 'unitOfMeasure': 'Millimeters of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Absolute Values of SBP and DBP', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Baseline (Day 21, Pre-dose): SBP', 'categories': [{'measurements': [{'value': '107.5', 'spread': '8.49', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: SBP', 'categories': [{'measurements': [{'value': '105.6', 'spread': '11.93', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: SBP', 'categories': [{'measurements': [{'value': '109.7', 'spread': '7.96', 'groupId': 'OG000'}]}]}, {'title': 'Baseline (Day 21, Pre-dose): DBP', 'categories': [{'measurements': [{'value': '62.7', 'spread': '5.31', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: DBP', 'categories': [{'measurements': [{'value': '58.4', 'spread': '5.87', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: DBP', 'categories': [{'measurements': [{'value': '62.2', 'spread': '5.06', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.', 'unitOfMeasure': 'Millimeters of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Change From Baseline in Oral Temperature', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.12', 'spread': '0.314', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, Pre-dose) and Day 10', 'description': 'Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Degrees Celsius', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Change From Baseline in Oral Temperature', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.249', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Degrees Celsius', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Change From Baseline in Oral Temperature', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Day 22', 'categories': [{'measurements': [{'value': '-0.13', 'spread': '0.242', 'groupId': 'OG000'}]}]}, {'title': 'Day 25', 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.286', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Degrees Celsius', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Change From Baseline in Pulse Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.5', 'spread': '6.27', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, Pre-dose) and Day 10', 'description': 'Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Beats per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Change From Baseline in Pulse Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.3', 'spread': '7.44', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Beats per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Change From Baseline in Pulse Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Day 22', 'categories': [{'measurements': [{'value': '-7.1', 'spread': '7.48', 'groupId': 'OG000'}]}]}, {'title': 'Day 25', 'categories': [{'measurements': [{'value': '-1.5', 'spread': '6.17', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Beats per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Change From Baseline in Respiratory Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.3', 'spread': '2.62', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, Pre-dose) and Day 2', 'description': 'Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Breaths per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Change From Baseline in Respiratory Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.3', 'spread': '2.36', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Breaths per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Change From Baseline in Respiratory Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Day 22', 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.90', 'groupId': 'OG000'}]}]}, {'title': 'Day 25', 'categories': [{'measurements': [{'value': '0.8', 'spread': '2.37', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Breaths per minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment A: Change From Baseline in SBP and DBP', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}], 'classes': [{'title': 'SBP', 'categories': [{'measurements': [{'value': '-3.3', 'spread': '9.67', 'groupId': 'OG000'}]}]}, {'title': 'DBP', 'categories': [{'measurements': [{'value': '-5.4', 'spread': '5.96', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 1, Pre-dose) and Day 10', 'description': 'SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Millimeters of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment B: Change From Baseline in SBP and DBP', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment B: GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment treatment B- GSK3640254 200 mg once daily from Days 11 to 20.'}], 'classes': [{'title': 'SBP', 'categories': [{'measurements': [{'value': '-0.5', 'spread': '8.56', 'groupId': 'OG000'}]}]}, {'title': 'DBP', 'categories': [{'measurements': [{'value': '-2.0', 'spread': '5.75', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Millimeters of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Change From Baseline in SBP and DBP', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'title': 'Day 22: SBP', 'categories': [{'measurements': [{'value': '-1.9', 'spread': '10.84', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: SBP', 'categories': [{'measurements': [{'value': '2.2', 'spread': '8.67', 'groupId': 'OG000'}]}]}, {'title': 'Day 22: DBP', 'categories': [{'measurements': [{'value': '-4.3', 'spread': '4.75', 'groupId': 'OG000'}]}]}, {'title': 'Day 25: DBP', 'categories': [{'measurements': [{'value': '-0.5', 'spread': '4.78', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.', 'unitOfMeasure': 'Millimeters of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment C: AUC(0-t) for GSK3640254', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '51840', 'spread': '48.8', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3', 'description': 'Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment C: AUC From Time Zero to the End of the Dosing Interval at Steady State (AUC[0-tau]) for GSK3640254', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '22920', 'spread': '37.3', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3', 'description': 'Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Cmax for GSK3640254', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '1450', 'spread': '41.7', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3', 'description': 'Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Plasma Concentration at the End of the Dosing Interval (Ctau) for GSK3640254', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '729.5', 'spread': '35.5', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3', 'description': 'Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment C: Tmax for GSK3640254', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '4.500', 'groupId': 'OG000', 'lowerLimit': '2.00', 'upperLimit': '8.03'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3', 'description': 'Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Treatment C: t1/2 for GSK3640254', 'denoms': [{'units': 'Participants', 'counts': [{'value': '18', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '29.556', 'spread': '16.9', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3', 'description': 'Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'AUC(0-t) for Alpha-hydroxymetoprolol', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '531.3', 'spread': '159.4', 'groupId': 'OG000'}, {'value': '487.9', 'spread': '174.4', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.92', 'ciLowerLimit': '0.49', 'ciUpperLimit': '1.71', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'AUC(0-infinity) for Alpha-hydroxymetoprolol', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '682.8', 'spread': '34.1', 'groupId': 'OG000'}, {'value': '632.8', 'spread': '50.7', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.93', 'ciLowerLimit': '0.74', 'ciUpperLimit': '1.16', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Cmax for Alpha-hydroxymetoprolol', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '45.70', 'spread': '199.8', 'groupId': 'OG000'}, {'value': '39.21', 'spread': '212.6', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.86', 'ciLowerLimit': '0.43', 'ciUpperLimit': '1.72', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Tmax for Alpha-hydroxymetoprolol', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.033', 'groupId': 'OG000', 'lowerLimit': '1.00', 'upperLimit': '6.00'}, {'value': '4.000', 'groupId': 'OG001', 'lowerLimit': '1.00', 'upperLimit': '8.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 't1/2 for Alpha-hydroxymetoprolol', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '8.040', 'spread': '31.4', 'groupId': 'OG000'}, {'value': '8.339', 'spread': '23.0', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'AUC(0-t) for 36-hydroxymontelukast', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '234.2', 'spread': '47.2', 'groupId': 'OG000'}, {'value': '230.9', 'spread': '59.1', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.99', 'ciLowerLimit': '0.75', 'ciUpperLimit': '1.29', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukas. 36-hydroxymontelukast is a metabolite of montelukast. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'AUC(0-infinity) for 36-hydroxymontelukast', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '252.5', 'spread': '48.2', 'groupId': 'OG000'}, {'value': '249.3', 'spread': '58.7', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.99', 'ciLowerLimit': '0.75', 'ciUpperLimit': '1.29', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Cmax for 36-hydroxymontelukast', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '24.62', 'spread': '45.7', 'groupId': 'OG000'}, {'value': '23.22', 'spread': '55.0', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.94', 'ciLowerLimit': '0.73', 'ciUpperLimit': '1.22', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Tmax for 36-hydroxymontelukast', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.000', 'groupId': 'OG000', 'lowerLimit': '3.00', 'upperLimit': '8.03'}, {'value': '6.000', 'groupId': 'OG001', 'lowerLimit': '4.00', 'upperLimit': '8.13'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 't1/2 for 36-hydroxymontelukast', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '5.310', 'spread': '14.3', 'groupId': 'OG000'}, {'value': '5.644', 'spread': '15.1', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'AUC(0-t) for 5-hydroxyomeprazole', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '713.5', 'spread': '38.0', 'groupId': 'OG000'}, {'value': '785.1', 'spread': '24.7', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.10', 'ciLowerLimit': '0.93', 'ciUpperLimit': '1.30', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'AUC(0-infinity) for 5-hydroxyomeprazole', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '767.4', 'spread': '30.9', 'groupId': 'OG000'}, {'value': '762.0', 'spread': '25.6', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.99', 'ciLowerLimit': '0.83', 'ciUpperLimit': '1.19', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Cmax for 5-hydroxyomeprazole', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '181.1', 'spread': '63.1', 'groupId': 'OG000'}, {'value': '203.3', 'spread': '28.6', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '1.12', 'ciLowerLimit': '0.88', 'ciUpperLimit': '1.44', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Tmax for 5-hydroxyomeprazole', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.000', 'groupId': 'OG000', 'lowerLimit': '2.05', 'upperLimit': '12.07'}, {'value': '6.000', 'groupId': 'OG001', 'lowerLimit': '1.50', 'upperLimit': '12.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 't1/2 for 5-hydroxyomeprazole', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.580', 'spread': '15.4', 'groupId': 'OG000'}, {'value': '1.569', 'spread': '13.5', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'AUC(0-t) for 1-hydroxymidazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '31.07', 'spread': '33.0', 'groupId': 'OG000'}, {'value': '28.07', 'spread': '37.0', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.90', 'ciLowerLimit': '0.75', 'ciUpperLimit': '1.09', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'AUC(0-infinity) for 1-hydroxymidazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '31.86', 'spread': '32.5', 'groupId': 'OG000'}, {'value': '28.99', 'spread': '36.6', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.91', 'ciLowerLimit': '0.76', 'ciUpperLimit': '1.09', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Cmax for 1-hydroxymidazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '7.933', 'spread': '53.8', 'groupId': 'OG000'}, {'value': '6.722', 'spread': '48.1', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of geometric least square mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.85', 'ciLowerLimit': '0.65', 'ciUpperLimit': '1.10', 'estimateComment': 'A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Tmax for 1-hydroxymidazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.000', 'groupId': 'OG000', 'lowerLimit': '0.25', 'upperLimit': '3.00'}, {'value': '1.000', 'groupId': 'OG001', 'lowerLimit': '0.25', 'upperLimit': '4.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 't1/2 for 1-hydroxymidazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.632', 'spread': '15.6', 'groupId': 'OG000'}, {'value': '3.717', 'spread': '21.0', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Ratio of Cmax of Alpha-hydroxymetoprolol to Metoprolol', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.7869', 'spread': '0.76896', 'groupId': 'OG000'}, {'value': '0.7066', 'spread': '0.93732', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (metoprolol) and its metabolite (alpha-hydroxymetoprolol). Ratio of Cmax of metabolite to parent drug has been presented.', 'unitOfMeasure': 'Ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Ratio of AUC(0-infinity) of Alpha-hydroxymetoprolol to Metoprolol', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.733', 'spread': '1.6208', 'groupId': 'OG000'}, {'value': '1.449', 'spread': '1.6511', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (metoprolol) and its metabolite (alpha-hydroxymetoprolol). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.', 'unitOfMeasure': 'Ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Ratio of Cmax of 36-hydroxymontelukast to Montelukast', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.06766', 'spread': '0.025068', 'groupId': 'OG000'}, {'value': '0.06308', 'spread': '0.025951', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (montelukast) and its metabolite (36-hydroxymontelukast). Ratio of Cmax of metabolite to parent drug has been presented.', 'unitOfMeasure': 'Ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Ratio of AUC(0-infinity) of 36-hydroxymontelukast to Montelukast', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.09182', 'spread': '0.033472', 'groupId': 'OG000'}, {'value': '0.08562', 'spread': '0.036555', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (montelukast) and its metabolite (36-hydroxymontelukast). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.', 'unitOfMeasure': 'Ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Ratio of Cmax of 5-hydroxyomeprazole to Omeprazole', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.9461', 'spread': '0.56833', 'groupId': 'OG000'}, {'value': '0.8810', 'spread': '0.49954', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (omeprazole) and its metabolite (5-hydroxyomeprazole). Ratio of Cmax of metabolite to parent drug has been presented.', 'unitOfMeasure': 'Ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Ratio of AUC(0-infinity) of 5-hydroxyomeprazole to Omeprazole', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.151', 'spread': '0.66463', 'groupId': 'OG000'}, {'value': '1.077', 'spread': '0.59178', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (omeprazole) and its metabolite (5-hydroxyomeprazole). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.', 'unitOfMeasure': 'Ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Ratio of Cmax of 1-hydroxymidazolam to Midazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.5286', 'spread': '0.23819', 'groupId': 'OG000'}, {'value': '0.4955', 'spread': '0.20616', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (midazolam) and its metabolite (1-hydroxymidazolam). Ratio of Cmax of metabolite to parent drug has been presented.', 'unitOfMeasure': 'Ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}, {'type': 'SECONDARY', 'title': 'Ratio of AUC(0-infinity) of 1-hydroxymidazolam to Midazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment A: Probe Substrates', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1.'}, {'id': 'OG001', 'title': 'Treatment C: Probe Substrates + GSK3640254 200 mg', 'description': 'All treated participants received a single dose of treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.4677', 'spread': '0.19853', 'groupId': 'OG000'}, {'value': '0.4618', 'spread': '0.20637', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (midazolam) and its metabolite (1-hydroxymidazolam). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.', 'unitOfMeasure': 'Ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK Parameter Population. Only those participants with data available at the specified time points were analyzed.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'All Treated Participants', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 milligram \\[mg\\], metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1; followed by treatment B- GSK3640254 200 mg once daily from Days 11 to 20; further followed by treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'periods': [{'title': 'Treatment Period 1 (Days 1 to 10)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '20'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '20'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}]}]}, {'title': 'Treatment Period 2 (Days 11 to 20)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '20'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '19'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}]}]}, {'title': 'Treatment Period 3 (Days 21 to 26)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '19'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '19'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}]}]}], 'recruitmentDetails': 'This study was conducted in the United States.', 'preAssignmentDetails': 'A total of 20 participants were enrolled and received study treatment.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'All Treated Participants', 'description': 'All treated participants received a single dose of treatment A: Probe substrates (caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1; followed by treatment B- GSK3640254 200 mg once daily from Days 11 to 20; further followed by treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '36.4', 'spread': '9.65', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '7', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '13', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'categories': [{'title': 'Black or African American', 'measurements': [{'value': '9', 'groupId': 'BG000'}]}, {'title': 'White - Arabic/North African Heritage', 'measurements': [{'value': '2', 'groupId': 'BG000'}]}, {'title': 'White - White/Caucasian/European Heritage', 'measurements': [{'value': '9', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'Safety Population consisted of all participants who received at least 1 dose of study medication.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2021-04-12', 'size': 888021, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2022-02-18T07:11', 'hasProtocol': True}, {'date': '2021-07-19', 'size': 682523, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2022-02-18T07:13', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE', 'maskingDescription': 'This is a single-group, single-arm study that has no masking.'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'This is a single-sequence, one-way drug interaction study.'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 20}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2020-12-16', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-12', 'completionDateStruct': {'date': '2021-03-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-12-22', 'studyFirstSubmitDate': '2020-06-05', 'resultsFirstSubmitDate': '2022-03-03', 'studyFirstSubmitQcDate': '2020-06-05', 'lastUpdatePostDateStruct': {'date': '2024-01-05', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2022-03-03', 'studyFirstPostDateStruct': {'date': '2020-06-11', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2022-05-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-03-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time t (AUC[0-t]) for Caffeine', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine. Area under the plasma concentration-time curve from time zero to time t, to be calculated using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'AUC From Time Zero Extrapolated to Infinity (AUC[0-infinity]) for Caffeine', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) for Caffeine', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine.'}, {'measure': 'Time to Cmax (Tmax) for Caffeine', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine.'}, {'measure': 'Apparent Terminal Phase Half-life (t1/2) for Caffeine', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine.'}, {'measure': 'AUC(0-t) for Metoprolol', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'AUC(0-infinity) for Metoprolol', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'Cmax for Metoprolol', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol.'}, {'measure': 'Tmax for Metoprolol', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol.'}, {'measure': 't1/2 for Metoprolol', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol.'}, {'measure': 'AUC(0-t) for Montelukast', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'AUC(0-infinity) for Montelukast', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'Cmax for Montelukast', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast.'}, {'measure': 'Tmax for Montelukast', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast.'}, {'measure': 't1/2 for Montelukast', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast.'}, {'measure': 'AUC(0-t) for Flurbiprofen', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'AUC(0-infinity) for Flurbiprofen', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'Cmax for Flurbiprofen', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.'}, {'measure': 'Tmax for Flurbiprofen', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.'}, {'measure': 't1/2 for Flurbiprofen', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.'}, {'measure': 'AUC(0-t) for Omeprazole', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'AUC(0-infinity) for Omeprazole', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'Cmax for Omeprazole', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole.'}, {'measure': 'Tmax for Omeprazole', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole.'}, {'measure': 't1/2 for Omeprazole', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole.'}, {'measure': 'AUC(0-t) for Midazolam', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'AUC(0-infinity) for Midazolam', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'Cmax for Midazolam', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam.'}, {'measure': 'Tmax for Midazolam', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam.'}, {'measure': 't1/2 for Midazolam', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam.'}, {'measure': 'AUC(0-t) for Digoxin', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'AUC(0-infinity) for Digoxin', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'Cmax for Digoxin', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin.'}, {'measure': 'Tmax for Digoxin', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin.'}, {'measure': 't1/2 for Digoxin', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin.'}, {'measure': 'AUC(0-t) for Pravastatin', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'AUC(0-infinity) for Pravastatin', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'Cmax for Pravastatin', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin.'}, {'measure': 'Tmax for Pravastatin', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin.'}, {'measure': 't1/2 for Pravastatin', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin.'}], 'secondaryOutcomes': [{'measure': 'Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'timeFrame': 'Up to Day 26', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAE was defined as any untoward medical occurrence that, at any dose, results in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect and other situations according to medical or scientific judgement.'}, {'measure': 'Treatment A: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.'}, {'measure': 'Treatment B: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.'}, {'measure': 'Treatment C: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.'}, {'measure': 'Treatment A: Absolute Values of Hematocrit', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.'}, {'measure': 'Treatment B: Absolute Values of Hematocrit', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.'}, {'measure': 'Treatment C: Absolute Values of Hematocrit', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.'}, {'measure': 'Treatment A: Absolute Values of Hemoglobin', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.'}, {'measure': 'Treatment B: Absolute Values of Hemoglobin', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.'}, {'measure': 'Treatment C: Absolute Values of Hemoglobin', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.'}, {'measure': 'Treatment A: Absolute Values of Erythrocytes', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.'}, {'measure': 'Treatment B: Absolute Values of Erythrocytes', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.'}, {'measure': 'Treatment C: Absolute Values of Erythrocytes', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.'}, {'measure': 'Treatment A: Absolute Values of Erythrocytes Mean Corpuscular Volume', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.'}, {'measure': 'Treatment B: Absolute Values of Erythrocytes Mean Corpuscular Volume', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.'}, {'measure': 'Treatment C: Absolute Values of Erythrocytes Mean Corpuscular Volume', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.'}, {'measure': 'Treatment A: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.'}, {'measure': 'Treatment B: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.'}, {'measure': 'Treatment C: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.'}, {'measure': 'Treatment A: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, urea. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.'}, {'measure': 'Treatment B: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, and urea. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.'}, {'measure': 'Treatment C: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium and urea. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.'}, {'measure': 'Treatment A: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.'}, {'measure': 'Treatment B: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.'}, {'measure': 'Treatment C: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.'}, {'measure': 'Treatment A: Absolute Values of Albumin, Globulin, Protein', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.'}, {'measure': 'Treatment B: Absolute Values of Albumin, Globulin, Protein', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.'}, {'measure': 'Treatment C: Absolute Values of Albumin, Globulin, Protein', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.'}, {'measure': 'Treatment A: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.'}, {'measure': 'Treatment B: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, and gamma-glutamyl transferase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.'}, {'measure': 'Treatment C: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, gamma-glutamyl transferase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.'}, {'measure': 'Treatment A: Absolute Values of Amylase, Lipase', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.'}, {'measure': 'Treatment B: Absolute Values of Amylase, Lipase', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.'}, {'measure': 'Treatment C: Absolute Values of Amylase, Lipase', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.'}, {'measure': 'Treatment A: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment B: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment C: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment A: Change From Baseline in Hematocrit', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment B: Change From Baseline in Hematocrit', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment C: Change From Baseline in Hematocrit', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment A: Change From Baseline in Hemoglobin', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment B: Change From Baseline in Hemoglobin', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment C: Change From Baseline in Hemoglobin', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment A: Change From Baseline in Erythrocytes', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment B: Change From Baseline in Erythrocytes', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment C: Change From Baseline in Erythrocytes', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment A: Change From Baseline in Erythrocytes Mean Corpuscular Volume', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment B: Change From Baseline in Erythrocytes Mean Corpuscular Volume', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment C: Change From Baseline in Erythrocytes Mean Corpuscular Volume', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment A: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment B: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment C: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment A: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, and urea. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment B: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, and urea. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment C: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium and urea. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment A: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment B: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment C: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment A: Change From Baseline in Albumin, Globulin, Protein', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment B: Change From Baseline in Albumin, Globulin, Protein', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment C: Change From Baseline in Albumin, Globulin, Protein', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment A: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment B: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, and gamma-glutamyl transferase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment C: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, gamma-glutamyl transferase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment A: Change From Baseline in Amylase, Lipase', 'timeFrame': 'Baseline (Day -1) and Day 10', 'description': 'Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment B: Change From Baseline in Amylase, Lipase', 'timeFrame': 'Baseline (Day 10) and Day 20', 'description': 'Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment C: Change From Baseline in Amylase, Lipase', 'timeFrame': 'Baseline (Day 20), Days 22 and 25', 'description': 'Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': "Treatment A: Absolute Values for Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Fridericia's Formula (QTcF)", 'timeFrame': 'Baseline (Day 1, Pre-Dose) and Day 10', 'description': 'Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.'}, {'measure': 'Treatment B: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.'}, {'measure': 'Treatment C: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.'}, {'measure': 'Treatment A: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF', 'timeFrame': 'Baseline (Day 1, Pre-dose) and Day 10', 'description': 'Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment B: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment C: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment A: Absolute Values of Oral Temperature', 'timeFrame': 'Baseline (Day 1, Pre-dose) and Day 10', 'description': 'Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.'}, {'measure': 'Treatment B: Absolute Values of Oral Temperature', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.'}, {'measure': 'Treatment C: Absolute Values of Oral Temperature', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.'}, {'measure': 'Treatment A: Absolute Values of Pulse Rate', 'timeFrame': 'Baseline (Day 1, Pre-dose) and Day 10', 'description': 'Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.'}, {'measure': 'Treatment B: Absolute Values of Pulse Rate', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.'}, {'measure': 'Treatment C: Absolute Values of Pulse Rate', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.'}, {'measure': 'Treatment A: Absolute Values of Respiratory Rate', 'timeFrame': 'Baseline (Day 1, Pre-dose) and Day 2', 'description': 'Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.'}, {'measure': 'Treatment B: Absolute Values of Respiratory Rate', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.'}, {'measure': 'Treatment C: Absolute Values of Respiratory Rate', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.'}, {'measure': 'Treatment A: Absolute Values of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)', 'timeFrame': 'Baseline (Day 1, Pre-dose) and Day 10', 'description': 'SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.'}, {'measure': 'Treatment B: Absolute Values of SBP and DBP', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.'}, {'measure': 'Treatment C: Absolute Values of SBP and DBP', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.'}, {'measure': 'Treatment A: Change From Baseline in Oral Temperature', 'timeFrame': 'Baseline (Day 1, Pre-dose) and Day 10', 'description': 'Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment B: Change From Baseline in Oral Temperature', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment C: Change From Baseline in Oral Temperature', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment A: Change From Baseline in Pulse Rate', 'timeFrame': 'Baseline (Day 1, Pre-dose) and Day 10', 'description': 'Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment B: Change From Baseline in Pulse Rate', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment C: Change From Baseline in Pulse Rate', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment A: Change From Baseline in Respiratory Rate', 'timeFrame': 'Baseline (Day 1, Pre-dose) and Day 2', 'description': 'Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment B: Change From Baseline in Respiratory Rate', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment C: Change From Baseline in Respiratory Rate', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment A: Change From Baseline in SBP and DBP', 'timeFrame': 'Baseline (Day 1, Pre-dose) and Day 10', 'description': 'SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment B: Change From Baseline in SBP and DBP', 'timeFrame': 'Baseline (Day 11, Pre-Dose) and Day 20', 'description': 'SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment C: Change From Baseline in SBP and DBP', 'timeFrame': 'Baseline (Day 21, Pre-Dose), Days 22 and 25', 'description': 'SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.'}, {'measure': 'Treatment C: AUC(0-t) for GSK3640254', 'timeFrame': 'Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3', 'description': 'Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'Treatment C: AUC From Time Zero to the End of the Dosing Interval at Steady State (AUC[0-tau]) for GSK3640254', 'timeFrame': 'Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3', 'description': 'Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.'}, {'measure': 'Treatment C: Cmax for GSK3640254', 'timeFrame': 'Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3', 'description': 'Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.'}, {'measure': 'Treatment C: Plasma Concentration at the End of the Dosing Interval (Ctau) for GSK3640254', 'timeFrame': 'Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3', 'description': 'Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.'}, {'measure': 'Treatment C: Tmax for GSK3640254', 'timeFrame': 'Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3', 'description': 'Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.'}, {'measure': 'Treatment C: t1/2 for GSK3640254', 'timeFrame': 'Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3', 'description': 'Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.'}, {'measure': 'AUC(0-t) for Alpha-hydroxymetoprolol', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'AUC(0-infinity) for Alpha-hydroxymetoprolol', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'Cmax for Alpha-hydroxymetoprolol', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol.'}, {'measure': 'Tmax for Alpha-hydroxymetoprolol', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol.'}, {'measure': 't1/2 for Alpha-hydroxymetoprolol', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol.'}, {'measure': 'AUC(0-t) for 36-hydroxymontelukast', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukas. 36-hydroxymontelukast is a metabolite of montelukast. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'AUC(0-infinity) for 36-hydroxymontelukast', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'Cmax for 36-hydroxymontelukast', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast.'}, {'measure': 'Tmax for 36-hydroxymontelukast', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast.'}, {'measure': 't1/2 for 36-hydroxymontelukast', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast.'}, {'measure': 'AUC(0-t) for 5-hydroxyomeprazole', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'AUC(0-infinity) for 5-hydroxyomeprazole', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'Cmax for 5-hydroxyomeprazole', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole.'}, {'measure': 'Tmax for 5-hydroxyomeprazole', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole.'}, {'measure': 't1/2 for 5-hydroxyomeprazole', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole.'}, {'measure': 'AUC(0-t) for 1-hydroxymidazolam', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'AUC(0-infinity) for 1-hydroxymidazolam', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.'}, {'measure': 'Cmax for 1-hydroxymidazolam', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam.'}, {'measure': 'Tmax for 1-hydroxymidazolam', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam.'}, {'measure': 't1/2 for 1-hydroxymidazolam', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam.'}, {'measure': 'Ratio of Cmax of Alpha-hydroxymetoprolol to Metoprolol', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (metoprolol) and its metabolite (alpha-hydroxymetoprolol). Ratio of Cmax of metabolite to parent drug has been presented.'}, {'measure': 'Ratio of AUC(0-infinity) of Alpha-hydroxymetoprolol to Metoprolol', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (metoprolol) and its metabolite (alpha-hydroxymetoprolol). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.'}, {'measure': 'Ratio of Cmax of 36-hydroxymontelukast to Montelukast', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (montelukast) and its metabolite (36-hydroxymontelukast). Ratio of Cmax of metabolite to parent drug has been presented.'}, {'measure': 'Ratio of AUC(0-infinity) of 36-hydroxymontelukast to Montelukast', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (montelukast) and its metabolite (36-hydroxymontelukast). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.'}, {'measure': 'Ratio of Cmax of 5-hydroxyomeprazole to Omeprazole', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (omeprazole) and its metabolite (5-hydroxyomeprazole). Ratio of Cmax of metabolite to parent drug has been presented.'}, {'measure': 'Ratio of AUC(0-infinity) of 5-hydroxyomeprazole to Omeprazole', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (omeprazole) and its metabolite (5-hydroxyomeprazole). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.'}, {'measure': 'Ratio of Cmax of 1-hydroxymidazolam to Midazolam', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (midazolam) and its metabolite (1-hydroxymidazolam). Ratio of Cmax of metabolite to parent drug has been presented.'}, {'measure': 'Ratio of AUC(0-infinity) of 1-hydroxymidazolam to Midazolam', 'timeFrame': 'Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (midazolam) and its metabolite (1-hydroxymidazolam). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['GSK3640254', 'Human immunodeficiency virus (HIV) infections', 'Drug interaction', 'Pharmacokinetics', 'Probe substrate'], 'conditions': ['HIV Infections']}, 'referencesModule': {'references': [{'pmid': '36822839', 'type': 'BACKGROUND', 'citation': 'Zhang Y, Johnson M, Joshi S, Yazdani P, Zhan J, Wen B, Bainbridge V, Gartland M, Lataillade M. Open-label, drug-drug interaction study between the HIV-1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants. Br J Clin Pharmacol. 2023 Jul;89(7):2236-2245. doi: 10.1111/bcp.15699. Epub 2023 Mar 13.'}]}, 'descriptionModule': {'briefSummary': 'This is an open-label, single sequence study that is being conducted to investigate the potential drug-drug interaction (DDI) when GSK3640254 is co-administered with a cocktail of cytochrome P450 (CYP) enzymes and transporter probe substrates in healthy participants. This study will aid in understanding these interactions and resulting changes in exposure (if any) when drugs that are metabolized via these pathways are given in combination with GSK3640254. The study will consist of a Screening period and 3 sequential treatment regimens. Participants will be administered a single dose of probe substrate drugs (caffeine 200 milligram (mg), metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg and pravastatin 40 mg) on Day 1. Participants will then receive GSK3640254 200 mg once daily on Days 11 to 20 followed by co-administration of probe substrate drugs with GSK3640254 on Day 21.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '50 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Participant must be 18 to 50 years of age inclusive, at the time of signing the informed consent.\n* Participants who are overtly healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination (including cardiopulmonary examination), laboratory tests, and cardiac monitoring (history and ECG).\n* Body weight more than or equal to (\\>=) 50.0 kilograms (kg) (110 pounds \\[lbs\\]) for men and \\>=45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 31.0 kilogram per square meter (kg/m\\^2) (inclusive).\n* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n* Male participants should not engage in intercourse while confined in the clinic. There is no need for an extended period of double barrier use or prolonged abstinence after study discharge.\n* A female participant is eligible to participate if she is not pregnant or breastfeeding and at least one of the following conditions applies:\n* Is not a woman of childbearing potential (WOCBP) or\n* Is a WOCBP and using a non-hormonal contraceptive method that is highly effective, with a failure rate of less than (\\<) 1 percent (%) for 28 days before intervention, during the intervention period, and for at least 28 days after the last dose of study intervention.\n* A WOCBP must have a negative highly sensitive serum pregnancy test at Screening and check-in (Day-1).\n* Capable of giving signed informed consent, which includes compliance with the requirements and restrictions, listed in the informed consent form (ICF) and in the protocol.\n\nExclusion Criteria:\n\n* Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).\n* A pre-existing condition interfering with normal gastrointestinal (GI) anatomy or motility (e.g., gastro-esophageal reflux disease, gastric ulcers, gastritis) or hepatic and/or renal function that could interfere with the absorption, metabolism, and/or excretion of the study intervention or render the participant unable to take oral study intervention.\n* Prior cholecystectomy surgery.\n* Any history of significant underlying psychiatric disorder, including, but not limited to, schizophrenia, bipolar disorder with or without psychotic symptoms, other psychotic disorders, or schizotypal (personality) disorder.\n* Any history of major depressive disorder with or without suicidal features, or anxiety disorders that required medical intervention (pharmacologic or not) such as hospitalization or other inpatient treatment and/or chronic (\\>6 months) outpatient treatment.\n\nParticipants with other conditions such as adjustment disorder or dysthymia that have required shorter term medical therapy (\\<6 months) without inpatient treatment and are currently well-controlled clinically or resolved may be considered for entry after discussion and agreement with the ViiV Healthcare (VH)/GlaxoSmithKline (GSK) Medical Monitor.\n\n* Any pre-existing physical or other psychiatric condition (including alcohol or drug abuse), which, in the opinion of the investigator (with or without psychiatric evaluation), could interfere with the participant's ability to comply with the dosing schedule and protocol evaluations or which might compromise the safety of the participant.\n* Medical history of cardiac arrhythmias, prior myocardial infarction in the past 3 months, or cardiac disease or a family or personal history of long QT syndrome.\n* History of asthma, bronchospasm, or sleep apnea.\n* History of chronic musculoskeletal pain (myalgias).\n* History of rhabdomyolysis.\n* History of a bleeding disorder.\n* History of Raynaud's disease.\n* History indicative of an increased risk of a cardiac arrhythmia or cardiac disease, including the following:\n* History of cardiac arrhythmias or palpitations associated with presyncope or syncope, or history of unexplained syncope.\n* History of clinically relevant cardiac disease including symptomatic or asymptomatic arrhythmias (including but not limited to ventricular fibrillation, ventricular tachycardia, any degree of atrioventricular block, Brugada syndrome, Wolff-Parkinson-White syndrome, and sinus bradycardia, defined as heart rate less than 50 beats per minute (bpm) based on vital signs or ECG), presyncope or syncopal episodes, or additional risk factors for torsades de pointes (e.g., heart failure).\n* History of clinically relevant structural cardiac disease including hypertrophic obstructive cardiomyopathy.\n* History of hypokalemia.\n* History of heart disease (e.g., coronary heart disease).\n* Presence of hepatitis B surface antigen at Screening or within 3 months prior to starting study intervention.\n* Positive hepatitis C antibody test result at Screening or within 3 months prior to starting study intervention and positive on reflex to hepatitis C Ribonucleic Acid (RNA).\n* Positive HIV-1 and 2 antigen/antibody immunoassay at Screening.\n* ALT\\>=1.5 × upper limit of normal (ULN). A single repeat of ALT is allowed within a single screening period to determine eligibility.\n* Bilirubin \\>=5 × ULN (isolated bilirubin \\>=5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin \\<35%). A single repeat of any laboratory abnormality is allowed within a single screening period to determine eligibility.\n* Any acute laboratory abnormality at Screening which, in the opinion of the investigator, should preclude participation in the study of an investigational compound.\n* Any Grade 2 to 4 laboratory abnormality at Screening, with the exception of lipid abnormalities (e.g., total cholesterol, triglycerides), and ALT, will exclude a participant from the study unless the investigator can provide a compelling explanation for the laboratory result(s) and has the assent of the sponsor.\n* A positive test result for drugs of abuse (including marijuana), alcohol, or cotinine (indicating active current smoking) at Screening or before the first dose of study intervention.\n* Unable to refrain from the use of prescription or nonprescription drugs including vitamins, herbal and dietary supplements (including St John's wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study intervention and for the duration of the study.\n* Treatment with any vaccine within 30 days prior to receiving study intervention.\n* Unwillingness to abstain from excessive consumption of any food or drink containing grapefruit and grapefruit juice, Seville oranges, blood oranges, or pomelos or their fruit juices within 7 days prior to the first dose of study intervention(s) until the end of the study.\n* Participation in another concurrent clinical study or prior clinical study (with the exception of imaging trials) prior to the first dosing day in the current study: 30 days, 5 half-lives, or twice the duration of the biological effect of the study intervention (whichever is longer).\n* Prior exposure to GSK3640254 in another clinical study.\n* Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 56 days.\n* Any positive (abnormal) response confirmed by the investigator on a screening clinician- or qualified designee-administered Columbia-Suicide Severity Rating Scale (C-SSRS).\n* SBP \\<100 mm Hg. Up to 2 repeats are allowed for confirmation.\n* Any significant arrhythmia or ECG finding (e.g., prior myocardial infarction in the past 3 months, symptomatic bradycardia, non-sustained or sustained atrial arrhythmias, non-sustained or sustained ventricular tachycardia, any degree of atrioventricular block, or conduction abnormality) which will interfere with the safety for the individual participant.\n* Exclusion criteria for screening ECG (a single repeat is allowed for eligibility determination): Heart rate- \\<50 or \\>100 bpm, PR interval- \\>200 milliseconds and QTcF- \\>450 milliseconds.\n* History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of \\>14 units. One unit is equivalent to 8 grams (g) of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine, or 1 (25 mL) measure of spirits.\n* Unable to refrain from tobacco or nicotine-containing products within 3 months prior to Screening.\n* History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.\n* History of aspirin allergy.\n* A participant with known or suspected active coronavirus disease of 2019 (COVID-19) infection OR contact with an individual with known COVID-19, within 14 days of study enrollment."}, 'identificationModule': {'nctId': 'NCT04425902', 'briefTitle': 'Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults', 'organization': {'class': 'INDUSTRY', 'fullName': 'ViiV Healthcare'}, 'officialTitle': 'Effects of GSK3640254 on the Single-Dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin) in Healthy Subjects', 'orgStudyIdInfo': {'id': '213052'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Probe Substrates/GSK3640254 200 mg/Probe Substrates+GSK3640254', 'description': 'All participants will receive a single dose of treatment A: Probe substrates (caffeine 200 milligram \\[mg\\], metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1; followed by treatment B- GSK3640254 200 mg on Days 11 to 20; further followed by treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.', 'interventionNames': ['Drug: GSK3640254 200 mg', 'Drug: Caffeine 200 mg', 'Drug: Metoprolol 100 mg', 'Drug: Montelukast 10 mg', 'Drug: Flurbiprofen 100 mg', 'Drug: Omeprazole 40 mg', 'Drug: Midazolam 5 mg (2.5 mL)', 'Drug: Digoxin 0.25 mg', 'Drug: Pravastatin 40 mg']}], 'interventions': [{'name': 'GSK3640254 200 mg', 'type': 'DRUG', 'description': 'GSK3640254 will be available as oral tablets at unit dose strength of 100 mg.', 'armGroupLabels': ['Probe Substrates/GSK3640254 200 mg/Probe Substrates+GSK3640254']}, {'name': 'Caffeine 200 mg', 'type': 'DRUG', 'description': 'Caffeine will be available as oral tablets at unit dose strength of 200 mg.', 'armGroupLabels': ['Probe Substrates/GSK3640254 200 mg/Probe Substrates+GSK3640254']}, {'name': 'Metoprolol 100 mg', 'type': 'DRUG', 'description': 'Metoprolol will be available as oral tablets at unit dose strength of 100 mg.', 'armGroupLabels': ['Probe Substrates/GSK3640254 200 mg/Probe Substrates+GSK3640254']}, {'name': 'Montelukast 10 mg', 'type': 'DRUG', 'description': 'Montelukast will be available as oral tablets at unit dose strength of 10 mg.', 'armGroupLabels': ['Probe Substrates/GSK3640254 200 mg/Probe Substrates+GSK3640254']}, {'name': 'Flurbiprofen 100 mg', 'type': 'DRUG', 'description': 'Flurbiprofen will be available as oral tablets at unit dose strength of 100 mg.', 'armGroupLabels': ['Probe Substrates/GSK3640254 200 mg/Probe Substrates+GSK3640254']}, {'name': 'Omeprazole 40 mg', 'type': 'DRUG', 'description': 'Omeprazole will be available as oral capsules at unit dose strength of 40 mg.', 'armGroupLabels': ['Probe Substrates/GSK3640254 200 mg/Probe Substrates+GSK3640254']}, {'name': 'Midazolam 5 mg (2.5 mL)', 'type': 'DRUG', 'description': 'Midazolam will be available as syrup for oral administration at unit dose strength of 2 milligram per milliliter (mg/mL).', 'armGroupLabels': ['Probe Substrates/GSK3640254 200 mg/Probe Substrates+GSK3640254']}, {'name': 'Digoxin 0.25 mg', 'type': 'DRUG', 'description': 'Digoxin will be available as oral tablet at unit dose strength of 0.25 mg.', 'armGroupLabels': ['Probe Substrates/GSK3640254 200 mg/Probe Substrates+GSK3640254']}, {'name': 'Pravastatin 40 mg', 'type': 'DRUG', 'description': 'Pravastatin will be available as oral tablet at unit dose strength of 40 mg.', 'armGroupLabels': ['Probe Substrates/GSK3640254 200 mg/Probe Substrates+GSK3640254']}]}, 'contactsLocationsModule': {'locations': [{'zip': '89113', 'city': 'Las Vegas', 'state': 'Nevada', 'country': 'United States', 'facility': 'GSK Investigational Site', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}], 'overallOfficials': [{'name': 'GSK Clinical Trials', 'role': 'STUDY_DIRECTOR', 'affiliation': 'ViiV Healthcare'}]}, 'ipdSharingStatementModule': {'url': 'https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR'], 'timeFrame': 'Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.', 'ipdSharing': 'YES', 'description': "Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/", 'accessCriteria': 'Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'ViiV Healthcare', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}